Molecular Immunology 38 (2001) 637–660
Review
Structure and function of major histocompatibility complex (MHC) class I
specific receptors expressed on human natural killer (NK) cells
Francisco Borrego a , Juraj Kabat a , Dae-Ki Kim a , Louis Lieto a , Kerima Maasho a ,
José Peña b , Rafael Solana b , John E. Coligan a,∗
a
Receptor Cell Biology Section, Laboratory of Allergic Diseases, NIAID, NIH, Twinbrook II, Room 205, 12441 Parklawn Dr., Rockville, MD 20852, USA
b Department of Immunology, School of Medicine, “Reina Sofı́a” Hospital, Córdoba University, Avda Menendez Pidal s/n, 14004 Córdoba, Spain
Accepted 8 November 2001
Abstract
Natural killer (NK) cells express receptors that are specific for MHC class I molecules. These receptors play a crucial role in regulating
the lytic and cytokine expression capabilities of NK cells. In humans, three distinct families of genes have been defined that encode for
receptors of HLA class I molecules. The first family identified consists of type I transmembrane molecules belonging to the immunoglobulin
(Ig) superfamily and are called killer cell Ig-like receptors (KIR). A second group of receptors belonging to the Ig superfamily, named ILT
(for immunoglobulin like transcripts), has more recently been described. ILTs are expressed mainly on B, T and myeloid cells, but some
members of this group are also expressed on NK cells. They are also referred to as LIRs (for leukocyte Ig-like receptor) and MIRs (for
macrophage Ig-like receptor). The ligands for the KIR and some of the ILT receptors include classical (class Ia) HLA class I molecules,
as well as the nonclassical (class Ib) HLA-G molecule. The third family of HLA class I receptors are C-type lectin family members and
are composed of heterodimers of CD94 covalently associated with a member of the NKG2 family of molecules. The ligand for most
members is the nonclassical class I molecule HLA-E. NKG2D, a member of the NKG2 family, is expressed as a homodimer, along with the
adaptor molecule DAP10. The ligands of NKG2D include the human class I like molecules MICA and MICB, and the recently described
ULBPs. Each of these three families of receptors has individual members that can recognize identical or similar ligands yet signal for
activation or inhibition of cellular functions. This dichotomy correlates with particular structural features present in the transmembrane
and intracytoplasmic portions of these molecules.
In this review we will discuss the molecular structure, specificity, cellular expression patterns, and function of these HLA class I receptors,
as well as the chromosomal location and genetic organization. © 2002 Elsevier Science Ltd. All rights reserved.
Keywords: NK cells; Inhibitory receptor; KIR; CD94/NKG2; ILT
1. Introduction
NK cells are a heterogeneous lymphoid population defined by a CD3− , CD16+ (Fc␥RIIIA), CD56+ (N-CAM)
surface phenotype and are characterized by their ability to
inherently lyse a great variety of cell types (referred to as
target cells) that have been transformed or infected with
Abbreviations: CTL, cytotoxic T lymphocyte; HCMV, human cytomegalovirus; ILT, immunoglobulin-like transcript; ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-based
inhibition motif; KIR, killer immunoglobulin-like receptor; LRC,
leukocyte receptor cluster; LIR, leukocyte immunoglobulin-like receptor; NCR, natural cytotoxicity receptors; NK, natural killer; SH2,
Src-homology-domain 2; SHP, SH2-containing tyrosine phosphatase
∗ Corresponding author. Tel.: +1-301-496-8247; fax: +1-301-480-9084.
E-mail address: jcoligan@niaid.nih.gov (J.E. Coligan).
viruses. NK cell lysis of target cells does not require prior
sensitization of the host and is not restricted by major histocompatibility complex (MHC) encoded molecules (Moretta
et al., 1996; Lanier, 1998); however, target cell lysis often
correlates with the downregulation of some or all of the
MHC class I molecules expressed by the target cells. This
observation led to the “missing self” hypothesis of NK
cell recognition (Ljunggren and Karre, 1990), whereby the
postulated role of NK cells is to destroy cells that have
downregulated expression of self-MHC class I molecules, a
common feature of virally-infected and transformed cells.
NK cells can recognize and lyse target cells by two basic
mechanisms: natural cytotoxicity and antibody dependent
cell cytotoxicity (ADCC). For so called natural cytotoxicity, a large variety of receptors have been identified that
can recognize target cells directly. Some of these activating
0161-5890/02/$ – see front matter © 2002 Elsevier Science Ltd. All rights reserved.
PII: S 0 1 6 1 - 5 8 9 0 ( 0 1 ) 0 0 1 0 7 - 9
638
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
receptors are mainly expressed on NK cells, whereas others
can be expressed on other cell types. Recently described
NK cell specific receptors are NKp46, NKp44 and NKp30,
referred to as natural cytotoxicity receptors (NCR) by their
discoverers (Moretta et al., 2000). The target cell ligands
for these receptors are not known, except for a recent report suggesting that haemagglutinins on virus-infected cells
can be recognized by NKp46 (Mandelboim et al., 2001).
Cell surface expression of these three NCRs is closely coordinated and the ability of NK cells to kill most target
cells is directly related to the level of surface expression.
Roda-Navarro et al. (2000) and Vitale et al. (2001) recently
described an additional NK cell specific molecule, NKp80,
that functions as a coreceptor for cytolysis, thereby enhancing NK cell function stimulated by other receptors. NKp80
is a type II transmembrane protein belonging to the C-type
lectin family of receptors and is encoded in the NK complex, whereas the members of the NCR are type I proteins
belonging to the Ig superfamily. Another NK cell receptor
that is expressed mainly by NK cells and activated CD8+
T cells is 2B4 (CD244), whose ligand is CD48 (Nakajima
et al., 1999; Nakajima and Colonna, 2000; Chuang et al.,
2001). NTB-A is a very recently described coreceptor that
also triggers cytolytic activity, but only by NK cells expressing high surface densities of NCR (Bottino et al., 2001).
KIRs and CD94/NKG2 family members that are specific
for MHC class I molecules that function as activating receptors are also apparently limited to expression on NK cells
and a subpopulation of T cells (see Fig. 1). NKG2D is a
homodimeric activating receptor expressed on NK cells, a
fraction of CD8+ ␣+ T cells, and ␣+ T cell clones (Wu
et al., 1999). The ligands for NKG2D are the stress-induced
class I like molecules MICA, MICB (Steinle et al., 2001)
and ULBPs (Cosman et al., 2001). For a more detailed review of NK cell activating receptors see recent reviews by
Moretta et al. (2001) and Biassoni et al. (2001).
There are several receptors that can activate NK cell lytic
activity that are not unique to NK cells. These include CD2
(Nakamura et al., 1991; Vivier et al., 1991b) and CD26
(Madueno et al., 1993) that are also expressed by CD4+ and
CD8+ T cells, CD69 (Borrego et al., 1999) is expressed by
all leukocytes after activation and 1 integrins (Perez-Villar
et al., 1996) are also expressed by many cell types.
The second type of target cell recognition utilized by NK
cells is indirect through the CD16 molecule and is referred
to as ADCC. CD16 is a receptor specific for the Fc portion
Fig. 1. Mechanism of signal transmission through human NK cell-receptors by HLA class 1 molecules. (A) The recruitment and activation of SHP-1
by inhibitory receptors leads to the dephosphorylation of proteins whose phosphorylation is necessary for conveying activating signals. Although SHP-2
can bind phosphorylated ITIMs, it is unclear whether it can function in the same context as SHP-1 (Olcese et al., 1996; Barford and Neel, 1998). (B)
Activating receptor complexes on NK cells associate with the ITAM bearing adaptor molecule DAP12 through charged residues in their transmembrane
regions. The membrane adaptor protein DAP10 does not have an ITAM in its cytoplasmic region, rather it has an YxxM motif that is a potential Src
homology 2 (SH2) binding domain. Activation of NK cells through ligation of these complexes leads to recruitment and activation of SH2 domain
containing protein tyrosine kinases, such as Syk or ZAP-70, except for NKG2D which recruits PI3-kinase.
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
of IgG. NK cells can be activated to lyse these target cells by
binding antibody molecules that have specificity for ligands
on these cells (Vivier et al., 1991a; Stahls et al., 1992).
The ligands recognized by receptors that activate NK cell
lytic activity are also present on normal cells. To prevent
wanton killing of “normal” cells a mechanism had to evolve
that would override the NK cell killing machinery that is always functional in mature NK cells (Lanier, 1998). In order
to accomplish this, NK cells express a variety of molecules
that inhibit NK cell activation through their recognition of
MHC encoded class I molecules. Class I molecules are expressed by virtually all normal cells, but tend to be downregulated by transformed and virally-infected cells (Ploegh,
1998; Algarra et al., 2000).
In humans, three families of such inhibitory NK receptors have been described. One major group is referred to as
killer Ig-like receptors (KIR). They possess two or three immunoglobulin (Ig) domains and each member interacts with
a different group of closely related HLA class I molecules
(Lanier, 1998) (see Fig. 2). A second group of receptors
known as ILT (immunoglobulin-like transcript) are also
members of the Ig superfamily. Some of the ILTs react with
a variety of HLA class I molecules (Colonna et al., 1999).
The third major group of NK cell inhibitory receptors is
the heterodimeric CD94/NKG2 C-type lectin proteins that
are specific for HLA-E (López-Botet and Bellon, 1999).
All of the inhibitory receptors from each group possess
immunoreceptor tyrosine-based inhibition motifs (ITIM) in
their cytoplasmic tails (Long, 1999) (see Figs. 1 and 2).
2. Killer immunoglobulin-like receptors (KIR)
KIRs comprise a family of molecules (Fig. 2) that are
encoded by multiple loci that (see Fig. 4) vary in certain
structural features and ligand specificity. A generally accepted nomenclature has been adopted to categorize these
molecules. According to this nomenclature, the acronym
KIR is followed by a suffix that describes the molecule. The
number of immunoglobulin-like extracellular domains they
possess is indicated by either 2D or 3D; the letter L or S
designates whether they have a long (L) or short (S) cytoplasmic domain; and finally, a code number is assigned to
each gene/molecule. During the 7th Human Leukocyte Differentiation Antigen Workshop, a new CD nomenclature was
proposed for the KIR and ILT gene families. It is based on
previous CD designation of some members of these families
and on the position of the genes on chromosome 19 (Andre et al., 2001) (Table 1). KIRs with long (L) cytoplasmic
tails are inhibitory and contain ITIM sequences, while those
with short (S) cytoplasmic tails activate NK cell cytotoxicity through interactions with the adaptor molecule, DAP12
(Lanier et al., 1998a) (see Fig. 2). NK cells expressing KIR
with ITIM sequences in their cytoplasmic domains (KIR2DL
and KIR3DL) are inhibited from lysing target cells that express MHC class I molecules reactive with the expressed
639
Table 1
Common names and CD nomenclature for ILT and KIR moleculesa
Common names
ILT5
ILT8
ILT4
ILT6
ILT11
ILT7
ILT1
ILT2
ILT3
ILT9
ILT10
KIR3DL7
KIR2DL2/L3
KIR2DL1
KIR2DS6
KIR2DL4
KIR3DL1/S1
KIR2DL5
KIR2DS5
KIR2DS1
KIR2DS4
KIR2DS2
KIR3DL2
CD designation
LIR3
LIR8
LIR2, MIR10
LIR4
LIR7
LIR6
LIR1, MIR7
LIR5
KIRC1
P58.2/p58.3
P58.1
KIRX
P70
P50.1
P50.3
P50.2
P140
CD85a
CD85b
CD85c
CD85d
CD85e
CD85f
CD86g
CD85h
CD85i
CD85j
CD85k
CD85l
CD85m
CD158z
CD158b1/b2
CD158a
CD158c
CD158d
CD158e1/e2
CD158f
CD158g
CD158h
CD158I
CD159j
CD158k
a The CD nomenclature of the KIRs and ILTs is based in part on the
previous CD designation of some members of these receptor families and
on the position of the genes on chromosome 19. An alphabetical order
has been assigned according to the centromeric–telomeric localization
of the genes. This nomenclature also takes into consideration the allelic
polymorphism of these gene families. KIR2DL2/KIR2DL3 corresponds to
CD158b1/b2 and KIR3DL1/KIR3DS1 corresponds to CD158e1/e2 (Andre
et al., 2001).
KIR molecule (Moretta and Moretta, 1997). This interaction usually also inhibits cytokine production by the effector
cells (D’Andrea et al., 1996). In contrast, the expression of
KIR without an ITIM (e.g. KIR2DS) by NK cells appears
to promote cytolysis against target cells expressing an appropriate MHC class I ligand (Moretta et al., 1995).
2.1. HLA class I ligand specificity
Even though the specificity for class I molecules displayed
by different KIR receptors is not as discriminatory as TCR,
they are capable of distinguishing among groups of HLA
class I molecules that have particular structural features.
For example, HLA-C molecules are the ligands for KIR2D
receptors, while subsets of HLA-B and HLA-A molecules
are the ligands for KIR3D receptors.
Several experimental methods have been used to elucidate the nature of the interaction between KIR receptors and
their ligands. Initial studies relied on site-directed mutagenesis of class I molecules and their transfection into class I
negative target cells followed by the analysis of their functional recognition with appropriate NK cell clones (Biassoni et al., 1995; Gumperz et al., 1997). Other investigators
640
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
have examined specificity by doing direct binding studies
with soluble forms of recombinant inhibitory receptors on
cells expressing specific class I molecules, or, in reverse, by
analyzing binding of class I oligomers to cells expressing
specific NK cell receptors (Winter and Long, 1997; Winter
et al., 1998; Allan et al., 1999). Ultimately, crystal structures of these receptors, some in complex with ligand, have
revealed the finer points of these interactions.
The crystal structure of three different KIR2DL receptors, KIR2DL1 (CD158a) (Fan et al., 1997), KIR2DL2
(CD158b1) (Snyder et al., 1999) and KIR2DL3 (CD158b2)
(Maenaka et al., 1999b), reveals that their immunoglobulinlike domains (D1 and D2) (Fig. 3A) are positioned at an
acute angle that is different for each receptor. The topology of the domains and their arrangement relative to each
other reveal a structural relationship of KIR2D with the
haematopoietic receptor family (Fan et al., 1997). The differences in the hinge angles observed in the different KIR2D
studied, as well as the differences observed in two crystal
forms of KIR2DL2, can be explained by different sets of
amino acid residue interactions found at the interdomain
interfaces. When complexed with class I molecules, the
receptors have a very similar interdomain orientation that is
dictated by the constraints imposed by ligand binding (Fan
et al., 2001). The crystal structure of the complex formed
by KIR2DL2 and HLA-Cw3 reveals that KIR2D receptors
bind in a nearly orthogonal orientation across the ␣1 and ␣2
helices of HLA class I molecules (Boyington et al., 2000).
The D1 domain interacts with polymorphic regions of the
Class I ␣1 helix, residues 69–84, and the D2 domain interacts with more conserved regions of the ␣2 helix, residues
145–151 (Fig. 3A). The KIR-HLA class I interface shows
a predominance of charged residue and hydrophilic residue
interactions that form an extensive array of hydrogen bonds
and salt bridges. Site-directed mutants that disrupt these
interface salt bridges substantially diminish binding affinity, supporting the crucial role for charged residues in HLA
recognition. The high impact of these mutations on KIR
binding affinity suggests that the relatively low affinity KIR
receptors achieve their ligand specificity by requiring a high
energy threshold for recognition (Boyington et al., 2000).
The “footprint” of KIR2DL2 on HLA-Cw3 involves six
loops interacting with conserved HLA-C residues (Fig. 3A).
Of the 12 HLA-Cw3 residues intimately involved in this in-
641
terface with KIR, 11 are invariant in all HLA-C molecules
(Fig. 3B). Of particular interest is the fact that the divergent residue lies in position 80 of the ␣1 helix. This residue
is Asn in HLA-Cw1, 3, 7 and 8, the ligands for KIR2DL2
and KIR2DL3, and Lys in HLA-Cw2, 4, 5, 6 and 15, the
ligand for KIR2DL1. Not surprisingly, of the 16 KIR2DL2
residues that interact with HLA-Cw3, all of them are identical in KIR2DL3, which also reacts with the same HLA-Cw3
and related allotypes. Fourteen of these residues are identical in KIR2DL1, the KIR2DL specific for the other group
of HLA-C molecules (Fig. 3B). The two different residues
are Lys 44 and Met 70 in KIR2DL2 and KIR2DL3 and Met
44 and Thr 70 in KIR2DL1. Not surprisingly, in the cocrystal structure it is possible to see the hydrogen bond formed
between Lys 44 of KIR2DL2 and Asn 80 of HLA-Cw3
(Boyington et al., 2000). In conjunction with the other hydrogen bonds and salt bridges, this hydrogen bond stabilizes
the interaction of KIR2DL2 with HLA-Cw3 and is apparently sufficient for determining the receptor-ligand specificity (Winter and Long, 1997). Very recently, the crystal
structure of KIR2DL1-HLA-Cw4 complex was published
(Fan et al., 2001). The footprint of this KIR receptor on the
HLA-Cw4 molecule is very similar to the KIR2DL2 footprint on HLA-Cw3. A major difference relating to specificity is that in KIR2DL1 Met 44 lies in an electronegatively charged pocket that hosts the side chain of Lys 80
from HLA-Cw4, whereas in the KIR2DL2/HLA-Cw3 interaction specificity relies on a hydrogen bond between Lys 44
in KIR2DL2 and Asn 80 in HLA-Cw3. The importance of
residue 70 in KIR/HLA-C interactions was shown by substituting Thr 70 in KIR2DL1 (see Fig. 3B) with Lys, which occurs naturally in KIR2DS1. This dramatically decreased the
binding of a KIR2DL1/Ig fusion protein to cells expressing
HLA-Cw4 (Biassoni et al., 1997). Mutagenesis experiments
(Winter et al., 1998) also showed the importance of Phe 45
for KIR2DL2 ligand binding. This residue forms hydrophobic contacts with Arg 75, Val 76 and Arg 79 in HLA-C
(Boyington et al., 2000). KIR2DS2 expresses a Tyr residue
at position 45 and its binding to cells expressing HLA-Cw3
is almost null, but substitution of this Tyr 45 by Phe was sufficient to permit specific binding of KIR2DS2 to HLA-Cw3.
There is less information about the features of how
KIR3D receptors interact with their ligands. KIR3DL1
binds to HLA-B alleles, specifically those of the Bw4
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 2. NK cell activating and inhibitory receptors with their signaling motifs and ligands. Positive and negative signs indicate charged residues in
transmembrane regions. The NKG2F gene codes for an ITIM like motif (YSEV); whether this sequence functions as an ITIM remains to be determined.
NKG2F and KIR2DL5 are depicted with stripes because only transcripts have been reported. If NKG2F is expressed, it is unknown if it partners
with CD94 or DAP12 (also striped). The putative KIR2DL5 molecule contains both ITIM and ITSM (immunoreceptor tyrosine-based switch motif)
motifs. KIR2DL4 is an activating receptor with an ITIM and a positively charged amino acid in its transmembrane domain. Despite this, evidence from
transfection experiments suggests that KIR2DL4 does not partner with FcR␥, DAP12 or DAP10 (Rajagopalan et al., 2001). KIR2DL4 and KIR2DL5 have
their extracellular domains in a D0/D2 configuration rather than the typical D1/D2 configuration. We have chosen to depict all KIRs, except KIR3DL2,
as monomers even though they may exist as dimers and oligomers especially after interaction with ligand (Boyington et al., 2001). Pende et al. (1996)
have demonstrated that KIR3DL2 is expressed as a dimer. Question marks denote that it is not clear that KIR2DL4 is a receptor for HLA-G, and no
evidence exists that CD94/NKG2E and CD94/NKG2H bind HLA-E.
642
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
Fig. 3. (A) Ribbon drawing showing the crystal structure of HLA-Cw3 bound to KIR2DL2. The 2m domain is yellow, HLA-Cw3 heavy chain is green
and the peptide is magenta. The KIR2DL2 molecule bound to HLA-Cw3 is blue. D1 and D2 domains in KIR2DL2 and the six loops (CC′ , EF, A′ B, FG,
BC and the hinge region) interacting with ␣1 and ␣2 domains of HLA-Cw3 are pointed out. The right view is rotated 90◦ from left view along the vertical
axis to illustrate that KIR binding is located at the carboxy-terminal end of the peptide and the corresponding region of the HLA-Cw3 ␣1 and ␣2 helices.
(B) Sequence alignments of the binding regions of KIR2DL1, KIR2DL2, HLA-Cw3 and HLA-Cw4. The conserved residues are indicated by dashes. Blue
spirals denote the ␣1 and ␣2 helices of HLA class I molecules. KIR2DL1 that align with KIR2DL2 contact residues are blue on a green background.
HLA-Cw4 residues that align with HLA-Cw3 contact residues are red on a yellow background (courtesy of Drs. Jeffrey C. Boyington and Peter D. Sun).
serotype (Gumperz et al., 1995) (see Fig. 2). A comparison among HLA-B molecules reveals that all but 3 of the
12 residues corresponding to the HLA-C residues that interface with KIR2DL are conserved across HLA-B and HLA-C
loci. The positions that differ are at position 69 (Ala or
Thr in HLA-Bw4 and Arg in HLA-C), position 76 (Glu in
HLA-Bw4 and Val in HLA-C) and position 80 (Asn, Thr
or Leu in HLA-Bw4 and Asn or Lys in HLA-C). So the
residues at these three positions, especially those at positions 69 and 76, likely determine KIR specificity for HLA-B
and HLA-C molecules. Indeed, the protein encoded by the
unusual HLA-B∗ 4601 allele, which is the product of an interlocus recombination, has HLA-Cw∗ 0102 residues 66–76
in its ␣1 helix and interacts with NK cells that recognize
HLA-Cw1 (Barber et al., 1996). Although all three domains
of KIR3D are required for binding of a soluble receptor to
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
HLA-B∗ 5101 (Rojo et al., 1997), it has been suggested that
the KIR3DL1/HLA-Bw4 interaction involves mainly the D1
and D2 domains (see Fig. 2) of KIR3D like the D1 and D2
domains in the KIR2DL2/HLA-Cw3 interaction (Boyington
et al., 2000).
2.1.1. Role of the peptide
The sequence of the peptide bound to MHC class I
molecules influences the interaction of class I complexes
with their corresponding KIRs. The crystal structure reveals
that KIR2DL2 directly contacts residues p7 and p8 of the
HLA-Cw3 associated peptide (Boyington et al., 2000). This
observation is corroborated by functional studies showing
that the lysis of target cells by NK clones exhibits peptide specificity (Zappacosta et al., 1997). Overt interactions
between the HLA-Cw4 peptide and KIR2DL1 are less apparent in the crystal structure (Fan et al., 2001); however,
studies with synthetic peptides have indicated that substitution of p8 Lys of the peptide with a negatively charged
residue results in the loss of KIR binding (Rajagopalan
and Long, 1997). This agrees with the observation that
KIR2DL1 has an electronegatively charged polar surface in
the area opposing the peptide p8 Lys side chain. As with
HLA-C molecules, the peptides bound to HLA-B molecules
have been shown to be important for the interaction with
KIR3D (Malnati et al., 1995; Peruzzi et al., 1996b) and,
likewise, peptide positions p7 and p8 have been shown to be
important for NK cell recognition of target cells expressing
HLA-B∗ 2705 (Peruzzi et al., 1996a).
2.1.2. Role of carbohydrate moiety
All human class I molecules have a carbohydrate moiety
attached to Asn 86. It is not clear if this carbohydrate moiety
plays a role in the interaction of HLA class I molecules with
KIRs. Based on the fact that cells transfected with HLA-C
mutant cDNAs lacking carbohydrate attachment sites are
less sensitive to NK cell recognition, Baba et al. (2000)
proposed that the N-linked carbohydrates interact with KIRs,
either directly or by influencing the conformation of HLA-C
at the KIR recognition site. However, it is not clear whether
these investigators took into account that class I molecules
devoid of carbohydrates often have a reduced efficiency for
cell surface expression. KIR inhibitory function is sensitive
to the levels of HLA class I cell surface expression (Borrego,
unpublished data).
2.1.3. Quantitative binding studies
Surface plasmon resonance and analytical ultracentrifugation studies with soluble proteins obtained from bacterial
expression systems have been utilized to examine the kinetics and affinity of the interaction between KIR and class I
molecules. HLA-C molecules bind KIR with very fast association and dissociation rate constants, which are more similar to the kinetics of the interactions of adhesion molecules
with their ligands than to those of TCR and their ligands
(Vales-Gomez et al., 1998a; Maenaka et al., 1999a). As de-
643
termined by the surface plasmon resonance experiments, the
half-life of KIR/HLA-C complexes is less than 1 s. Similarly, the half-life of complexes between adhesion molecules
and their ligands is less than 1.5 s, while the half-life of
TCR/MHC complexes is greater than 5 s (Vales-Gomez
et al., 1998b). KIR binds class I molecules with a favorable
binding entropy that is consistent with an optimally fixed
binding site, which is unlike TCR/peptide-MHC interactions that are characterized by unfavorable entropic changes,
suggesting that binding is accompanied by conformational
adjustments (Willcox et al., 1999).
What is the significance of the rapid kinetics of KIR/HLA
class I interaction for the biology of NK cells? A primary
physiological role of NK cells appears to be surveillance
for self-MHC class I proteins. For this function, they must
rapidly assess the expression of HLA class I proteins on the
surface of a cell as a sign of “normality”. Once that is determined, they must dissociate to continue the surveillance of
other cells. In this regard, it has been shown that NK cells can
interact with target cells expressing an inhibitory HLA class
I ligand without affecting the subsequent lysis of susceptible target cells (Lanier, 1998). This observation implies not
only a rapid association–dissociation rate for KIR/HLA-C
complexes, but also a rapid reversal of the inhibitory signal.
Despite the very high homology of the D1 and D2 domains of corresponding KIR2DS and KIR2DL molecules,
KIR2DS bind HLA-C molecules only very weakly
(Vales-Gomez et al., 1998a; Winter et al., 1998). This
difference is thought to have an underlying functional significance. Viewed simplistically, if activating and inhibitory
receptors in similar concentrations are competing for binding to the same HLA-C molecules, then the signals from
the inhibitory receptors are more likely to predominate.
This belies the more important question of why there are
activating receptors for class I molecules (see Section 5.3).
2.1.4. Role of metal ions as binding cofactors
Evidence indicates that KIR can bind certain metal ions,
but it is not clear if they have a functional role. The first
extracellular domain of KIR has an unusual abundance
of histidine residues that are capable of binding zinc ions
(Rajagopalan et al., 1995; Rajagopalan and Long, 1998).
The simultaneous replacement of six His by Ala residues
in the putative zinc binding sites abolished binding of zinc
to soluble KIR. Even more striking, the mutational disruption of a single exposed amino-terminal zinc-binding
motif alone was sufficient to impair the inhibitory function
of KIR. NK cells expressing such mutagenized KIR were
impaired in their inhibitory function, but surprisingly their
ability to bind HLA-C was apparently not affected. Surface plasmon resonance, analytical ultracentrifugation, and
chemical cross-linking experiments have shown that zinc
binding to KIR2D molecules induces multimerization of
KIR proteins that alters the kinetics of the KIR2D-HLA-C
interaction (Vales-Gomez et al., 2001). In the absence of
zinc, the binding reaction is a simple first-order interaction
644
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
with very fast association and dissociation rates. In contrast,
in the presence of zinc, the association and dissociation
phases of the KIR2D-HLA-C interaction became a mixture
of fast and slow rate components. Cobalt also induces KIR
dimerization increasing its affinity to HLA-C. The mutation
of the His residue most proximal to the amino terminus
to an Ala residue in KIR2D abolished cobalt binding and,
as expected, dimerization did not occur (Fan et al., 2000).
Within the KIR2DL2/HLA-Cw3 crystal complex, apart
from the class I peptide associated binding interface, KIR
molecules also make an additional contact with a neighboring related HLA-Cw3 in a peptide-independent manner.
Based on these observations and previous work by Davis
et al. (1999), Boyington et al. (2000) proposed that this
form of receptor-ligand oligomerization resembled the receptor clustering on the surface of NK cells during immune
synapse formation.
2.2. KIR2DL4 and KIR2DL5
KIR with two Ig domains exhibit a D1–D2 configuration, while KIR with three Ig domains have an order of
D0–D1–D2, but KIR2DL4 is unique among members of
the KIR family. cDNA clones encoding KIR2DL4 predict a
molecule with two Ig domains in a D0–D2 configuration (see
Fig. 2) (Selvakumar et al., 1996; Cantoni et al., 1998). It has
both an Arg residue in the transmembrane region and a long
cytoplasmic tail with a single ITIM. Therefore, KIR2DL4
molecules have features typical of both activating and inhibitory receptors leaving open the question of what type
of signals are transmitted by this receptor. Binding assays
with recombinant soluble KIR2DL4 showed that this receptor could bind HLA-G (Rajagopalan and Long, 1999), as
well as HLA-A3, -B46 and weakly to -B7 molecules (Cantoni et al., 1998). In contrast, data published by others (Allan et al., 1999; Navarro et al., 1999) suggest that HLA-G
binds ILT2 and ILT4, but not KIR2DL4.
Unlike other KIR molecules that show clonal distribution,
KIR2DL4 molecules have been reported to be expressed
on the surface of all peripheral NK cells (Rajagopalan and
Long, 1999). In contrast, others have reported (Ponte et al.,
1999) that KIR2DL4 is expressed on a significant proportion of NK cells in the decidua during the first trimester of
pregnancy and on all NK cells obtained from the placenta
at term, but is absent on NK cells from the mother’s peripheral blood. The fact that these studies employed different antibodies for detection of KIR2DL4 may have some
bearing on the reported discrepancies. Very recently, it has
been reported that KIR2DL4 is an activating receptor with
the unique feature of inducing IFN-␥ secretion but not cytotoxic potential in resting NK cells. In previously activated
NK cells, KIR2DL4 is capable of inducing cytotoxicity (Rajagopalan et al., 2001).
Recently transcripts for another type of KIR gene, called
KIR2DL5, have been detected in subpopulations of NK
cells and T cells, but as yet, no evidence for protein expression is available (Vilches et al., 2000a). KIR2DL5
molecules would have an extracellular configuration of the
D0–D2 type, like KIR2DL4 (Fig. 2). Although similar in
extracellular structure, KIR2DL4 has a single ITIM in its
cytoplasmic region, whereas KIR2DL5 has two ITIM motifs separated by 24 residues. The additional ITIM differs
from the consensus motif by having a Thr residue instead of
the I/V at position -2. This TxYxxV/I motif has been called
ITSM (immunoreceptor tyrosine-based switch motif) and is
present in a broad range of receptors, for example CD150.
Protein structures with this motif have been shown to bind
the SH2-containing protein tyrosine phosphatase SHP-2
and the inositol phosphatase SHIP, as well as the adaptor,
SH2 domain containing, protein 1A (SH2D1A/DSHP/SAP)
(Shlapatska et al., 2001). KIR2DL5 lacks the Arg residue
present in the transmembrane region of KIR2DL4 and, unlike KIR2DL4, transcripts are clonally expressed by NK
cells within an individual and expression is limited to the
“B” KIR haplotype (Vilches et al., 2000b).
2.3. Genetic organization and evolution of KIR receptors
The genes encoding the KIR are located on human chromosome 19q13.42 in a region called the leukocyte receptor cluster (LRC) (Fig. 4). Other members residing in the
LRC are the ILTs, leukocyte-associated inhibitory receptors
(LAIR), Fc␣R and NKp46 (Barten et al., 2001). All the
genes encoding two-Ig-domain KIRs, with the exception of
KIR2DL4 and KIR2DL5, have a pseudo exon 3 that has
remarkable similarity to the exon encoding the first Ig domain (D0) of the three Ig domain KIRs (Selvakumar et al.,
1997; Wilson et al., 1997, 2000; Vilches et al., 2000b). These
data are consistent with the hypothesis that genes encoding
the two-Ig-domain KIRs have evolved from a gene encoding a three-Ig-domain KIR through disablement of an exon
(Barten et al., 2001).
The KIR region is plastic in its organization and the
genes contained within exhibit isotypic and allotypic variation (Wilson et al., 2000; Barten et al., 2001). Over 100
highly homologous KIR sequences have been deposited in
databases and there are several alleles for each particular
KIR loci (Selvakumar et al., 1997). There is a high degree of diversity in KIR gene expression that arises from
haplotypic differences in gene number and allelic polymorphism (Uhrberg et al., 1997). There are a minimum of 15
different haplotypes, which based on the presence or absence of particular loci, allow for many different genotypes
(Uhrberg et al., 1997; Barten et al., 2001). There are three
loci (KIR2DL4, KIR3DL2 and KIR3DL7, previously known
as KIR3DL3) that are present in all haplotypes (Barten et al.,
2001). The conservation of gene structures and sequence homologies between the different KIR receptor haplotypes indicates that the LRC evolved by extensive gene duplication
and recombination with insertion and deletion mechanisms
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
645
Fig. 4. The human leukocyte receptor cluster (LRC) is a ∼1 mb region located on chromosome 19q13.42. Within this complex lie the ILTs, LAIRs, KIRs,
FcαR and NKp46 genes. KIR3DL7, KIR2DL4 and KIR3DL2 (in black) are framework loci present in all haplotypes. Note: this figure is not drawn to scale.
leading to KIR gene diversification (Shilling et al., 1998;
Kwon et al., 2000). The frequencies with which certain combinations of KIR loci are found in different individuals exceeded levels expected from random association (Uhrberg
et al., 1997) and is indicative of linkage disequilibrium of
alleles in haplotypes.
MHC class I molecules are characterized by their rapid
evolution and divergence. Khakoo et al. (2000) have shown
that, as would be expected, KIRs have also evolved very
rapidly. A comparison between human and chimpanzees
showed that their KIR families are very divergent, with only
three KIR families conserved between chimpanzees and humans. Relating to this divergence is the observation that
KIRs that recognize the orthologous human and chimpanzee
MHC ligands HLA-B and -C and Patr-B and Patr-C, respectively, are recognized by nonorthologous KIRs in these
species. As discussed in Section 2.1, KIR specificity for human MHC-C molecules is largely determined by the amino
acid residue at position 44 of the KIR-D1 domain; consistent
with this finding, the human and chimpanzee KIR that have
identical MHC-C specificity also have the identical residues
at this position. These observations show that KIR receptors
have evolved relatively rapidly, and that “catching up” with
class I molecules is not the only mechanism driving their
evolution (Khakoo et al., 2000).
3. Immunoglobulin-like transcripts (ILT)
In a search for new Ig superfamily members, several investigators isolated multiple cDNA clones that code for proteins with Ig-like domains and that had distinct expression
patterns in leukocytes (Samaridis and Colonna, 1997; Wagtmann et al., 1997). Those receptors are called ILT (also LIR
or MIR) and they can be categorized into three groups: those
containing ITIM motifs, those with short cytoplasmic tails
and a charged amino acid residue within the transmembrane
region, and one member that contains no transmembrane
segment and that is presumably a secreted molecule (Borges
et al., 1997). These receptors are expressed in a broad array
of cells including monocytes, macrophages, dendritic cells,
B, T and NK cells (Colonna et al., 1999). Of interest for
this review is ILT2 (LIR-1, MIR7, CD85j), the only member
of this family that is expressed on some NK cells (Colonna
et al., 1997; Cosman et al., 1997).
ILT2 has four extracellular Ig domains and four ITIMs in
its intracytoplasmic tail and it can bind a broad panel of HLA
class I molecules (Colonna et al., 1997; Cosman et al., 1997),
including HLA-G (Allan et al., 1999; Navarro et al., 1999)
(Fig. 2). In addition, ILT2 binds the human cytomegalovirus
class I homolog UL18 (Cosman et al., 1997; Vitale et al.,
1999). ILT2 interacts with the ␣3 domain of the class I and
UL18 proteins (Chapman et al., 1999), which probably explains its broad range of reactivity, as the ␣3 domain of class
I molecules shows the highest sequence conservation. Interestingly, ILT2 binds UL18 with higher affinity than class
I molecules. This supports the hypothesis that UL18 may
function to inhibit recognition by ILT2 bearing immune cells
of HCMV infected cells that have downregulated expression of classical class I molecules (Chapman et al., 1999).
The crystal structure of domains 1 and 2 (D1D2) of ILT2
has been solved and they are arranged at an acute angle that
resembles the structure of KIRs, but in contrast to KIR the
binding site of ILT2 to UL18 is located in a portion of D1
646
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
distant from the hinge region between D1 and D2 (Chapman et al., 2000). It has been proposed that the binding of
ILT2 to UL18 is similar to the interaction between the D1
domain of CD4 and the 2 domain of class II MHC proteins
(Chapman et al., 1999).
HLA-F is a nonclassical MHC encoded class I molecule
that has been shown to be expressed intracellularly, but not as
yet on the cell surface of restricted group of tissue types. Recently, Lepin et al. (2000) have shown that HLA-F tetramers
can stain cells expressing ILT2 and ILT4, and surface plasmon resonance studies demonstrated a direct molecular interaction of soluble forms of ILT2 and ILT4 with HLA-F.
These findings lead them to speculate that cells expressing
HLA-F on their surfaces, perhaps in the presence of a specific peptide, can reach the cell surface and interact with
cells expressing ILT2 and ILT4 thereby modulating the activation threshold of such immune effector cells.
ILT genes are clustered in the LRC centromeric to the
KIR (Fig. 4). In contrast to KIR genes, the ILT genes are
more stable in number, except for ILT6, which is present
in only one haplotype (Wilson et al., 2000). There are two
clusters of ILT genes that are separated by about 200KB
and that are transcribed in opposite directions. Two LAIR
genes are encoded between the two clusters of ILT genes
(Wende et al., 1999) (Fig. 4). ILT2 is expressed on most
myelomonocytic cells, B cells, dendritic cells, and subsets
of T cells and NK cells. One study indicated that all T cells
express ILT2, at least intracellularly, but only a fraction may
express it on the cell surface (Saverino et al., 2000). Like
other inhibitory receptors, the interaction of ILT2 with HLA
class I molecules on target cells inhibits killing of these cells,
including CD16-mediated activation by the NK cells and T
cell cytotoxicity induced by the TCR. It also inhibits B cell
and monocyte activation (Colonna et al., 1997).
4. C-type lectin receptors
The third family of human NK receptors for HLA class I
antigens are C-type lectin family members. Most members
of this family are expressed as heterodimers with CD94
covalently associated with a member of the NKG2 family
(Lazetic et al., 1996; Brooks et al., 1997; Carretero et al.,
1997; Bellon et al., 1999). The sole identified homodimer
in this family is the activating receptor NKG2D, a distantly
related member of the NKG2 family (Wu et al., 1999).
4.1. CD94/NKG2
Similar to KIRs, the CD94/NKG2 family of receptors has
individual members with activating and inhibitory features
that correlate with structural characteristics in their transmembrane and intracytoplasmic tails (López-Botet and Bellon, 1999) (see Figs. 1 and 2). The inhibitory members of
this family are NKG2A and an isoform of NKG2A generated
by alternative spliced pre-mRNA referred to as NKG2B. In
accordance with their inhibitory function, they have intracytoplasmic tails with two ITIMs. The activating forms are
NKG2C, -E and -H with NKG2E and -H being generated by
alternative splicing of the same pre-mRNA transcript. These
molecules have intracellular tails without ITIM motifs and a
charged amino acid in the transmembrane region necessary
for the association with DAP-12, an ITAM-bearing adaptor molecule (Bellon et al., 1999; López-Botet and Bellon,
1999) (see Fig. 1). An interesting member of the NKG2 family is NKG2F. So far, only the transcripts of this gene have
been detected, but they are present in most NK clones (Kim
and Coligan, unpublished data). The putative NKG2F protein has a charged residue in the transmembrane region, an
ITIM-like motif in the cytoplasmic tail and does not contain
any C-type lectin domain. However, a conserved 24-amino
acid sequence, present in all members of the NKG2 family,
suggests that NKG2-F could form heterodimers with CD94
(Plougastel and Trowsdale, 1997).
The ligand of CD94/NKG2 receptors is the nonclassical class I molecule HLA-E (Borrego et al., 1998; Braud
et al., 1998; Lee et al., 1998). In general, HLA-E cell
surface expression depends on specific peptides derived
from positions 3–11 of the signal sequence of classical
HLA class I molecules and HLA-G (Braud et al., 1997).
(AVMAPRTLVLLLSGALALTQTWA is the sequence for
the signal peptide of HLA-A2 molecules with the HLA-E
binding peptide shown in italics.) Thus, NK cells can monitor HLA-A, -B, -C and -G class I expression on cells
directly through their recognition by KIR and indirectly
through the recognition of HLA class I-derived peptides
complexed with HLA-E. HLA-A, -B, -C and -G signal
sequences can be grouped according to whether they have
a Met residue (shown in bold) at position p2 of the resulting HLA-E binding peptide or a Thr residue (see review
Posch et al., 1998). If present in sufficient levels (added exogeneously), either p2 Met or Thr containing peptides can
stabilize HLA-E surface expression; however, the affinity of
Thr containing peptides is significantly lower (Brooks et al.,
1999). Because of this lower affinity, class I molecules that
contain Thr at p2 of their signal sequence do not support the
production of sufficient endogenous peptide to affect the
stable expression of HLA-E on the cell surface. Once
the HLA-E/peptide complex is stable on the cell surface, it
must be recognized by CD94/NKG2A. As exemplified by
EBV protein BZLF-1, there are nonsignal sequence derived
peptides that stabilize HLA-E cell surface expression but
that are not recognized by CD94/NKG2A (Ulbrecht et al.,
1998; Brooks et al., 1999; López-Botet et al., 2000). While
CD94/NKG2C clearly can bind HLA-E (Braud et al., 1998;
Vales-Gomez et al., 1999), no such evidence has yet been
reported for CD94/NKG2E or CD94/NKG2H. Moreover, it
has been suggested that the ligand of CD94/NKG2H is not
HLA-E (Bellon et al., 1999).
Like the binding of KIRs to HLA-C, the binding of
CD94/NKG2A to HLA-E has very fast association and
dissociation rates and the binding affinity is relatively
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
low, about 10 M (Vales-Gomez et al., 1999; López-Botet
et al., 2000). The CD94/NKG2C activating receptor binds
to HLA-E with at least a 10-fold lower affinity than does
CD94/NKG2A. This mimics the binding relationship of
KIR activity and inhibitory receptors for HLA-C (see Section 2.1.4). The only peptide complexed with HLA-E that
was recognized with relatively high affinity (∼10 M) by
CD94/NKG2C was the leader peptide from HLA-G. This
finding is consistent with functional results reported by
Llano et al. (1998). These investigators examined the ability of NK clones expressing CD94/NKG2C to lyse 721.221
target cells that express HLA-E with different exogeneously
loaded peptides. They found that the HLA-G derived signal
sequence peptide, but not the equivalent p2 Met containing
peptides derived from HLA-C molecules, was capable of
sensitizing the 721.221 target cells for lysis.
The crystal structure of the extracellular portion of CD94
revealed a unique variation of the classical C-type lectin
fold (Boyington et al., 1999). In the CD94 crystal structure,
the carbohydrate-binding site is significantly altered and
the Ca2+ binding site appears nonfunctional. Since C-type
lectins require both of these sites to bind carbohydrate (Day,
1994), it seems unlikely that CD94 can do this. The fact that
CD94 crystalizes as a dimer gave licence to Boyington et al.
(1999) to predict the structure of CD94/NKG2 hetrodimers
and the location of the putative HLA-E binding site.
4.2. NKG2D
NKG2D is distantly related to the other members of the
NKG2 family and does not dimerize with CD94, rather it
is expressed as a homodimer (Wu et al., 1999). It is an
activating receptor expressed not only on NK cells, but
also on all TCR␥␦+ T cells and activated CD8+ TCR␣+
T cells (Bauer et al., 1999). The surface expression of
NKG2D requires the association with an adaptor protein
termed DAP10 (Wu et al., 1999) (see Figs. 1 and 2). The
ligands of NKG2D are MICA and MICB, which are encoded within the human MHC (Bauer et al., 1999). MICA
and MICB are stress-induced class I like molecules with
three extracellular domains that neither associate with
2 -microglobulin nor bind peptides. They are commonly
expressed on tumors of epithelial origin (Groh et al., 1996,
1999; Li et al., 1999). Considerable polymorphism has
been observed with 54 alleles of MICA and 16 alleles of
MICB so far identified (Bahram, 2000). At least one allele, MICA009, has been shown to be strongly associated
with disease, in this case Behcet’s disease (Mizuki et al.,
1997). It is not known whether all allelic gene products of
MICA/B bind to NKG2D; however, work by Cerwenka and
Lanier (2001) suggest that the affinity of binding is quite
variable. Recently Cosman et al. (2001) have shown that
the ULBP (1, 2, and 3) class I-like molecules are additional
ligands for NKG2D. These molecules have the class I related ␣1 and ␣2 domains but lack an ␣3 domain, and have
647
a glycosylphosphatidylinositol (GPI) linkage to the plasma
membrane. ULBPs show only low homology (23–26%
identity) to other members of the MHC class I family. ULBP
transcripts are detected in many normal tissues, and are
upregulated in colon and stomach tumors, but were shown
to be downregulated in a kidney tumor (Cosman et al.,
2001). Very interestingly, UL16, a human cytomegalovirus
glycoprotein, binds ULBPs and MICB, and a soluble form
of UL16 can block the interaction of ULBPs or MICB with
NKG2D suggesting a mechanism for viral interference of
NKG2D recognition (Cosman et al., 2001).
The engagement of NKG2D by MICA or MICB activates
the cytolytic response of NK cells, TCR␥␦+ T cells, as well
as some CD8+ TCR␣+ T cells (Wu et al., 1999). Similarly, the expression of ULBPs by NK cell-resistant target
cells confers susceptibility to NK cell cytotoxicity and stimulates cytokine production by NK cells (Cosman et al., 2001;
Kubin et al., 2001). NKG2D has been shown to complement the other activation receptors expressed on NK cells,
especially the functionally important NCR (see Section 1).
The killing of certain target cells has been shown to be
exclusively dependent on NCR expression by NK cells,
other target cells are only susceptible to NK cells expressing
NKG2D, and some target cells can be lysed by either NCR
or NKG2D bearing NK cells. This pattern of target-cell susceptibility to killing is likely dependent on the ligands that
they express (Pende et al., 2001).
It has been shown that fibroblast and endothelial cells
substantially increase MIC cell surface expression following infection by human cytomegalovirus (HCMV)
(Groh et al., 2001). MIC engagement of NKG2D augmented TCR-dependent cytolytic and cytokine responses
by HCMV-specific CD28− CD8+ ␣+ T cells, thereby
overcoming the downregulation of MHC class I molecules
induced by the virus. The ability of NKG2D to potently
enhance TCR mediated production of IL-2 and T cell proliferation suggest that it can function as a costimulatory
molecule on T cells. This was confirmed by showing that
it could substitute for CD28 costimulation by hyperactive
CD28− , CD8+ ␣+ T cells.
The crystal structure of the NKG2D-MICA complex revealed a NKG2D homodimer bound to a MICA monomer
in an interaction that is analogous to that seen for T cell
receptor-MHC class I protein complexes (Li et al., 2001).
Similar surfaces on each NKG2D monomer interact with
large and highly complementary areas of the ␣1 or ␣2
domains of MICA. NKG2D itself is more closely related
to CD94 than previously described members of the C-type
lectin family and like CD94, does not contain a putative
carbohydrate binding site or any of the features that are
characteristic of the Ca2+ binding sites of C-type lectins.
By surface plasmon resonance analysis, it was shown that
the equilibrium dissociation constant (Kd ), 1 mM at 37 ◦ C,
was one to two orders of magnitude stronger than NK cell
receptors previously analyzed, as well as many TCR interactions with MHC proteins. Kinetic analysis indicated that
648
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
the NKG2D-MICA interaction might be more stable than
TCR-ligand and other NK receptor-ligand complexes (Li
et al., 2001).
A mouse NKG2D has been described that is expressed
on NK cells, activated macrophages and activated CD8+ T
cells. The ligands for mouse NKG2D are H60 and Rae1
(Cerwenka et al., 2000; Diefenbach et al., 2000). In common with MICA and MICB, Rae-1 and H60 appear to be
up-regulated in a number of tumors. The over-expression
of Rae-1b and H60 in mouse tumors that do not naturally
express them resulted in NK-mediated immune rejection of
the tumors in vivo that was NKG2D dependent (Cerwenka
et al., 2001; Diefenbach et al., 2001). Sometimes NKG2D
tumor rejection requires CD8+ ␣ T cells (Diefenbach et al.,
2001) and Girardi et al. (2001) have shown that NKG2D+
␥␦ T cells are crucial for immune surveillance against malignant epidermal cells. The expression of Rae-1 and H60
increases in skin treated with the carcinogens. The killing
of Rae-1- and H60-positive skin cells by ␥␦ intraepithelial
lymphocytes requires both NKG2D and ␥␦ TCR, suggesting
that NKG2D provides a costimulatory signal for the TCR.
The chromosomal location of ULBPs on human chromosome 6 is syntenic with that of the RAE1 and H60 genes
on mouse chromosome 10 supporting the idea that they
are functional homologs (Cosman et al., 2001). Recently,
O’Callaghan et al. (2001) showed that H-60 competes with
a 25-fold higher affinity compared to RAE-1 for the same
NKG2D binding site.
4.3. NK complex: gene organization and evolutionary
perspective
The human NK complex and adjacent regions of chromosome 12 contain genes coding for C-type lectins, many
of which are highly relevant in NK cell biology (Renedo
et al., 2000; Hofer et al., 2001). The 28 genes identified
within the 2.5 Mb defined as the NK complex code for
C-type lectins, as well as proteins unrelated to immune
function (Fig. 5). The telomeric boundary is defined by the
C-type lectin gene DLEC/CLECSF11 expressed by monocyte derived dendritic cells (Arce et al., 2001). In the NK
complex lies the dendritic cell immunoreceptor (DCIR),
which codes for a C-type lectin found on blood monocytes
and granulocytes but not T or NK cells. The next C-type
lectin centromeric to DCIR is MAFA-L, an inhibitory C-type
lectin found on peripheral blood NK cells as well as basophils. Located next to MAFA-L are the ␣2-macroglobulin
(A2M) and the pregnancy zone protein (PZP) genes. These
two genes share 70% identity, are functional homologs, and
act as potent proteinase inhibitors (Bonacci et al., 2000).
Eighteen genes within the human NK complex code for
C-type lectin receptors, of which 13 are transcribed by
NK cells (MAFA-L, NKR-P1A, LLTI, CD69, AICL, KLRF1,
CLEC-2, CD94, NKG2A/B, NKG2C, NKG2D, NKG2E/H
and NKG2F). Four genes have been identified that code
for C-lectin type proteins, which are not expressed by NK
cells. These include the aforementioned DCIR, CLEC-1,
Fig. 5. The human NK complex is a ∼2.5 Mb region on chromosome 12p12–p13 with boundaries defined by DLEC/CLECSF11 on the telomeric side and
PRB3 on the centromeric side. The genes in bold code for C-type lectins, the genes in italics do not. Two of the NKG2 genes generate multiple proteins
through alternative splicing of pre-mRNA. NKG2A codes for the A and B protein isoforms which differ by the presence or absence of the protein
sequence encoded by exon 4, respectively. Likewise, NKG2E codes for both the E and H protein isoforms. The NKG2H transcript lacks the terminal
exon 7 of NKG2E. The magnified view of CD94 and the NKG2 family shows distances between genes and the direction of transcription. Note: this
figure is not drawn to scale.
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
DECTIN-1 and LOX-1. CLEC-1 and Dectin-1 are expressed primarily on dendritic cells and LOX-1 is expressed
in vascular endothelial cells (Yamanaka et al., 1998). In
addition, Ly-49L codes for a C-type lectin but most likely
does not produce an expressed protein (see below). PRB3
defines the centromeric boundary of the NK complex and
codes for a salivary, proline-rich protein. Examination of
the NK receptor mapping data indicates that the central region of the NK complex, from NKR-P1a to LY49L seems to
contain exclusively C-type lectin receptors. Flanking this region are several unrelated genes, which code for non-lectin
proteins. These include the previously mentioned A2M,
PZP and PRB3 as well as HPH1, M6PR, CHLR1, CHLR2,
MAGO, TKR-like and CSDA. On the telomeric part of the
NKC, near DCIR, lies HPH1, the human homolog of the
D. melanogaster polyhomeotic gene, which plays a role in
maintenance of the transcriptional repression state of HOX
genes. M6PR codes for the calcium dependent mannose
6-phosphate receptor, which is involved in the intracellular
649
transport of lysosomal enzymes. The CHLR1 and 2 genes
code for helicases. Centromeric to Ly-49 is MAGO, the human homolog of mago nashi, a Drosophilia embryo germ
plasm development protein (Zhao et al., 2000). Next lies the
heretofore-uncharacterized putative tyrosine kinase receptor
gene, TKR-like. The gene for cold shock domain protein
A (CSDA), a putative repressor of GM-CSF transcription,
follows the TKR-like gene (Cole et al., 1996).
DNA and protein sequence homology comparisons show
NKG2A, -C, -E, and -F to be a closely related cluster of genes
whereas NKG2D is no more similar to other members of
the NKG2 family than to CD94 (Glienke et al., 1998). Transcriptional start sites for NKG2D have been identified within
exon IV of NKG2F as well as closer to exon I of NKG2D
(Houchins et al., 1991; Plougastel and Trowsdale, 1997).
This suggests that NKG2D may be under the control of dual
promoters. The NKG2A, -C, -E and -F genes are highly similar in genomic organization (Fig. 6) and sequence and have
identical transcriptional orientation (Fig. 5). Sobanov et al.
Fig. 6. This shows the relative exon/intron structure of the CD94 gene and the genes of the NKG2 family. The CD94 gene is telomeric to the NKG2A
gene and has low homology with NKG2 gene family members. NKG2A has a non-coding initial exon represented by the diagonal lines. NKG2C and E
have a duplicated exon 3B. NKG2E also has an Alu sequence which crosses the intron 6-exon 7 junction. NKG2D is a large gene with several long
introns which are represented by ‘//’. Some NKG2D transcripts contain 131 noncoding nucleotides from NKG2F exon 4 at their 5′ end. Note: this figure
is not drawn to scale.
650
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
(1999) proposed that these NKG2 genes evolved through a
mechanism of consecutive gene duplication. It is probable
that an initial duplication event gave rise to NKG2A and a
second gene that underwent subsequent duplication events
to give rise to NKG2F and finally to NKG2C and -E. Prior
to this last duplication event, there was an internal duplication of exon 3. A two base pair insertion within exon 4 of
NKG2F lead to a frame shift which causes a premature stop
codon to be read and results in a short transcript lacking
an extracellular domain. Sequence comparison of NKG2C
and -E revealed that they have a remarkable 98% identity
in the 3 kb region upstream from their translation start sites,
whereas NKG2F shows only a 75% identity (Brostjan et al.,
2000). NKG2C and -E both contain a second version of exon
3 (exon 3b) within intron 2 (Fig. 6), which has yet to be
observed in any cDNA (Glienke et al., 1998). NKG2E also
contains an Alu element within the coding sequence of its
3′ end.
Multiple start sites for NKG2A transcripts have been identified ∼2.2 kb upstream from the start site of translation
by primer extension analysis and 5′ RACE mapping. All
NKG2A transcripts include a 5′ untranslated exon (Plougastel and Trowsdale, 1998; Brostjan et al., 2000). In addition
to transcripts for NKG2A, the NKG2A locus codes for a
pre-mRNA splice variant NKG2B that lacks an exon 4 encoded sequence. Similarly, NKG2E codes for both the -E and
-H protein isoforms. The NKG2H transcript lacks the terminal exon sequence present in NKG2E transcripts. CD94 lies
to the telomeric side of NKG2D in the NK complex. CD94
contains six exons, has a TATA less promoter, and multiple
transcription start sites (Rodriguez et al., 1998). The human
Ly49L gene is centromeric to NKG2A and fails to properly
splice exon 5 at its 3′ end leading to termination of transcription at a premature stop codon in intron 6, plus it appears to
have a defective polyadenylation site (Mager et al., 2001).
The low abundance of this truncated mRNA and the unlikelihood that a translated protein would be functional suggests
that the Ly49L gene is an evolutionary remnant (Barten and
Trowsdale, 1999).
Comparison of the MHC I receptors of mouse and human
NK cells indicates that the Ly49, CD94 and the NKG2 families existed before the divergence of the rodent and primate
lineages around 100 million years ago (Kumar and Hedges,
1998). Functional CD94/NKG2 receptors are found in both
mouse and human NK cells. However, Ly49 genes, while
functional in rodents, do not produce a detectable product
in humans (see above). The presence of the KIR genes in
primates, but not in rodents, suggests that the KIR genes
evolved after the two lineages diverged and in humans, the
KIR gene products assumed the functions executed by Ly49
proteins in mice. However, unlike humans, baboons and possibly other old world monkeys, express Ly49L as a secreted
protein (Mager et al., 2001), but it is difficult to envision a
functional role for a soluble Ly49 molecule. As in humans,
it seems more likely to be an evolutionary remnant. The
genes for CD94 and the NKG2 family are highly conserved
between humans and primates with fewer interspecies differences than the genomic average (Khakoo et al., 2000).
Chimpanzees have a species-specific duplication of NKG2C,
which is not observed in humans or rhesus monkeys (Khakoo
et al., 2000; LaBonte et al., 2000). NKG2B transcripts exist as an alternative splice product in both chimpanzees and
rhesus monkeys. In addition to the canonical transcripts, rhesus monkeys also have alternatively spliced pre-mRNAs for
NKG2C and -D that result in shorter transcripts (LaBonte
et al., 2000).
The most highly conserved primate NK cell receptors for class I molecules are those that interact with the
non-classical MHC class I molecules, i.e. members of the
CD94/NKG2 family. This is consistent with the fact that
the HLA-E gene sequence is highly conserved between humans and chimpanzees whereas the genes for the classical
MHC class I molecules (KIR ligands) show much greater
divergence between these same species (Arnaiz-Villena
et al., 1997; Knapp et al., 1998).
5. Signal transduction coupled to HLA class I
specific receptors
As previously stated, NK cells express both activating
and inhibitory cell surface receptors that interact with MHC
class I molecules (see Fig. 1). Inhibitory signaling receptors all possess cytoplasmic ITIMs, whereas the activating
receptors lack ITIMs and associate with adaptor molecules,
which are responsible for the transmission of the triggering
signal (Ravetch and Lanier, 2000). It has become apparent
that the effect or function of NK cells is regulated by a
balance between opposing signals delivered by the MHC
class I specific inhibitory receptors and by the activating
receptors responsible for NK cell triggering. Upon ligation
of activating receptors, NK cells can undergo blastogenesis, develop lytic capacity, produce cytokines, and show
enhanced migration. However, the simultaneous ligation
of activating receptors and inhibitory receptors with target
cell ligands usually results in a dominance of inhibitory
effects that downregulates the signals initiated via the activating pathways. The ligation of inhibitory receptors is
characterized by tyrosine phosphorylation of ITIMs and
subsequent recruitment and activation of phosphatases
(SHP-1 and SHP-2), which leads to the inhibition of various NK cell-mediated effector functions (Burshtyn et al.,
1996; Long, 1999; Tomasello et al., 2000a; Moretta et al.,
2001).
5.1. Inhibitory receptors: the ITIM and SHP-1/SHP-2
phosphatases
Initially, ITIMs were characterized by the amino acid
sequence YxxL/V, which was extended to I/V/L/SxYxxL/V
(Vivier and Daeron, 1997; Ravetch and Lanier, 2000;
Tomasello et al., 2000a). After ligation of inhibitory
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
receptors by MHC class I molecules, the first step in the
transmission of the inhibitory signal is the phosphorylation
of the ITIMs by a Src tyrosine kinase. Using a somatic
genetic model, Binstadt et al. (1996) showed a requirement
for p56lck in mediating KIR3DL tyrosine phosphorylation,
but others (Burshtyn et al., 1996) have shown that other Src
tyrosine kinases can also phosphorylate the ITIMs.
The phosphorylated ITIMs create the SH2 domain docking sites for recruiting and activating phosphatases (Burshtyn et al., 1996) (Fig. 1). The conserved aliphatic Y-2
residue (position 2 residues upstream of the Tyr) has been
shown to be important for phospho-ITIM containing peptides to bind SHP-1 and SHP-2 in “in vitro” studies (Burshtyn et al., 1996, 1997; Vely et al., 1997). In vivo studies
have shown that the membrane-proximal ITIM of KIR2DL
(Fig. 1) has an important role in the transmission of the inhibitory signal, while the membrane-distal ITIM has a less
relevant role. In addition, substitution of the conserved Y-2
residue in the membrane-proximal ITIM with Ala weakened the function of the receptor (Burshtyn et al., 1999). All
phospho-ITIMs studied so far have an affinity for SHP-1
and/or SHP-2 protein tyrosine phosphatases (Binstadt et al.,
1996; Burshtyn and Long, 1997; Leibson, 1997; Ono et al.,
1997). After pervanadate treatment of appropriate cells, both
phosphatases can be detected in immunoprecipates of KIR
and CD94/NKG2A (Campbell et al., 1996; Le Drean et al.,
1998; Bruhns et al., 1999). The importance of SHP-1 in KIR
signaling is highlighted by the observation that the overexpression of a catalytically inactive form of SHP-1 (dominant
negative) can reverse the inhibitory effect of KIR ligation for
both ADCC and natural cytotoxicity (Burshtyn et al., 1996).
On the other hand, since SHP-2 has been shown to be preferentially involved in activating signaling cascades (Huyer
and Alexander, 1999; Qu et al., 1999), the relevance for its
recruitment by the KIR and NKG2A ITIMs is unclear. The
fact that SHP-2 has been implicated in signal transmission
by CTLA4, a receptor whose engagement depresses T cell
activation, suggests SHP-2 can play a role in negative signaling events (Thompson and Allison, 1997).
Inhibitory KIRs and NKG2A molecules each contain two
ITIMs in their cytoptasmic tails. The membrane proximal
motif starts about 30 residues from the transmembrane segment. All inhibitory receptors, whether they contain one
or more ITIMs, have similar distances between the plasma
membrane and the membrane proximal ITIM (Bléry et al.,
2000). Although inhibitory KIRs and NKG2A molecules
have two very similar ITIM motifs that are spaced similarly
in the intracytoplasmic domains, they are orientated in opposite orientations. This is because KIRs and NKG2A are
type I and type II integral membrane proteins, respectively.
For KIR molecules, the membrane proximal motif appears
to be functionally more important (Burshtyn et al., 1999)
whereas the opposite is true for NKG2A (Kabat and Coligan,
unpublished observations). This difference appears to be
more related to the directional orientation of the molecules
than to the structure of the individual ITIMs. The amino acid
651
length between the two ITIMs in KIR and NKG2A is about
25 amino acid residues; a distance that is thought to be optimal for the recruitment of tandem SH2 containing phosphatases (Bléry et al., 2000). The simultaneous engagement
of SHP-1/-2 SH2 domains is required for maximal phosphatase catalytic activity (Pluskey et al., 1995; Pei et al.,
1996; Burshtyn et al., 1997).
The targets of catalytically activated SHP-1/-2 phosphatases are only beginning to be elucidated. The fact that
the simultaneous ligation of 2B4 (CD244) and KIR2DL1
or CD94/NKG2A completely abrogates phosphorylation
of 2B4 indicates that inhibition begins with the earliest
steps in the activation process (Watzl et al., 2000). Little
data exists in humans, but for mice several apparent targets of SHP-1 have been described and may explain the
inhibitory capabilities of KIRs and CD94/NKG2A. Analysis of Motheaten mice, which are genetically deficient in
SHP-1, revealed an increase in the phosphorylation state
of Src family kinases upon TCR stimulation of T cells
(Lorenz et al., 1996), as well as in the ITAM-containing,
tranducing molecules CD3 and CD3ε. Also in Motheaten
mice the adaptor protein linker (LAT) for T cell activation
is hyperphosphorylated and it can be dephorphorylated by
SHP-1 in vitro. In vivo, this dephosphorylation induces the
dissociation of LAT and PLC␥ in NK cells (Valiante et al.,
1996). The SLP-76 adaptor protein has also been shown to
be a target for SHP-1 in T and NK cells (Binstadt et al.,
1998) and SHP-1 can dephosphorylate ZAP-70 and Syk
(Plas et al., 1996; Dustin et al., 1999). These results indicate
that SHP-1 has the potential to terminate activating signals by dephosphorylating molecules that function early in
activation signalling pathways. However, a caveat to these
results is that SLP-76 (−/−) (Peterson et al., 1999) and LAT
(−/−) (Zhang et al., 1999) mice appear to have normal NK
cytolytic function indicating that there is either redundancy
in activation pathways or that SHP-1 dephosphorylation
of these molecules is not involved in deactivation signals.
Schematic models depicting the potential sites where inhibitory signals may interfere with NK cell activation signals
are shown in reviews by Bléry et al. (2000) and Long et al.
(2001).
When NK cells form conjugates with sensitive tumor
cells, receptor containing rafts become polarized to the site
of target recognition (Lou et al., 2000). This redistribution
of lipid rafts requires the activation of both Src and Syk family protein tyrosine kinases. In contrast, the engagement by
inhibitory KIRs on NK cells of HLA class I molecules on
resistant, MHC-bearing tumor targets blocks raft redistribution. This inhibition is dependent on the catalytic activity of
SHP-1, and supports a role for SHP-1 in inhibiting signal
transmission through inhibition of raft aggregation. Recently
it has been shown that the recruitment of SHP-1 to rafts
and its association with LAT was dramatically increased after TCR engagement suggesting that SHP-1 is also involved
in regulating raft-mediated T cell activation (Kosugi et al.,
2001).
652
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
5.2. Activating receptors: involvement of DAP12
and DAP10
Although the first MHC class I specific NK receptors described were inhibitory receptors, soon afterwards highly homologous receptors were found that functioned as NK activating receptors (Biassoni et al., 1996). These receptors have
short cytoplasmic tails and do not have an intracellular motif
that explains their triggering capacity. An adaptor protein,
called DAP12 or KARAP, was described that associates noncovalently with these short-tail NK receptors (Olcese et al.,
1997; Lanier et al., 1998a) (see Figs. 1 and 2). A positively
charged residue in the transmembrane region of the receptor
associates with a negatively charged residue in the transmembrane region of DAP12 serving to stabilize the interaction between these two proteins (Lanier et al., 1998b). Cell
surface expression of KIR2DS and CD94/NKG2C is greatly
enhanced by the association with DAP12 (Lanier et al.,
1998a,b). Crosslinking of DAP12 containing NK cell receptors results in cellular activation, as demonstrated by tyrosine phosphorylation of cellular proteins and upregulation of
early-activation antigens (Lanier et al., 1998a,b). DAP12 is
also expressed in peripheral blood monocytes, macrophages,
and dendritic cells, suggesting association with other receptors present in these cell types (Lanier et al., 1998b).
DAP12 is expressed as a homodimer and contains a
classical ITAM motif in its cytoplasmic domain (Fig. 1).
The ITAM contains two of the consensus YxxL amino
acid sequences spaced by 7 amino acids. Receptor clustering results in a rapid and transient phosphorylation of Tyr
residues within the ITAMs, thereby creating binding sites
for several SH2-domain containing cellular proteins such
as protein tyrosine kinases and adaptor molecules coupling
to downstream process (Isakov, 1997). The phosphorylated
DAP12 initiated activation pathway is similar to that of Tand B-cell antigen receptors. Studies of the binding of signal transducing molecules to the ITAMs of the CD3- chain
showed that ZAP70 bound specifically to biphosphorylated
but not to the mono- or unphosphorylated peptides (Zenner
et al., 1996) Evidence that the two YxxL in each ITAM
sequence are functionally distinct, emerged from mutations
of the Tyr or Leu residues in the N-terminal YxxL segment
of the membrane proximal ITAM of CD3- which abolished all signal transduction functions for this molecule.
In contrast, mutations of Tyr or Leu in the C-terminal
YxxL of the ITAM amino sequence abrogated signals for
IL-2 production, but did not prevent phosphorylation of
the N-terminal Tyr of the ITAM nor did it interfere with
other ITAM mediated functions (Sunder-Plassmann et al.,
1997).
DAP12 (−/−) mice have normal numbers of NK cells
and the repertoire of inhibitory MHC class I receptors is
intact (Bakker et al., 2000). As expected, the class I specific
Ly49 activating receptors were functionally impaired resulting in a diminished killing capacity for xenogenic tumor
cells; however, killing of several mouse tumor cell lines was
not affected indicating that DAP12 independent pathways
are involved in these instances. Other features presented by
DAP12 (−/−) mice include a resistance to peptide-induced
experimental autoimmune encephalomyelitis. Resistance
was associated with a strongly diminished production of
IFN-␥ by myelin peptide-reactive CD4+ T cells due to inadequate T cell priming in vivo. These data suggest that DAP12
signaling may be required for optimal antigen-presenting
cell (APC) function or inflammation (Bakker et al., 2000).
Similar results were obtained by Tomasello et al. (2000b)
using loss-of-function (dominant negative) mutant mice.
Human polycystic lipomembranous osteodysplasia with
sclerosing leukoencephalopathy (PLOSL), also known as
Nasu–Hakola disease, is a recessively inherited disease
characterized by a combination of psychotic symptoms
rapidly progressing to presenile dementia and bone cysts
restricted to the wrists and ankles. Genetic analyses of patients with this disease showed loss-of-function mutations
in DAP12. Curiously, no abnormalities in NK cell function
were detected in PLOSL patients homozygous for a null
allele of DAP12 (Paloneva et al., 2000).
Similar to the activating KIR and CD94/NKG2 receptors, NKG2D does not have an intracellular motif that accounts for the transmission of the triggering signal, but instead of DAP12, NKG2D associates with an adaptor protein
called DAP10 (Fig. 2) that is predominantly expressed in
hematopoietic cells. In its cytoplasmic domain, each DAP10
has the amino acid sequence YxxM that binds the SH2 domain of the p85 subunit of PI 3-kinase (Wu et al., 1999).
The sequence differs from the canonical YxxI/L sequence
present in tandem in ITAM motifs (Gergely et al., 1999).
Recent studies by Warren et al. (2001) demonstrated that
activating receptors are capable of stimulating NK cell lytic
function in the presence of ligated inhibitory receptors. This
was shown by using CD158b mAb that is equally reactive with activating KIR2DS2 and inhibitory KIR2D2 and
KIR2DL3 receptors. These investigators showed that the activating KIR2DS2 receptor could be stimulated without interference from the inhibitory KIR2DL2 and KIR2DL3 receptors by using low concentrations of CD158b mAb and
Fc␥RII+ P815 target cells. High concentrations of CD158b
resulted in the inhibition of the killing of the P815 target
cells. The authors postulated that recognition of the same
HLA ligand by co-expressed NK cell receptors may function
as a fail-safe mechanism for activating NK cells in situations whereby HLA concentrations on target cells are below
that capable of inhibiting NK cell function. This mechanism
could be effective if no other NK cell-activating receptors
and their appropriate target cell ligands are present. It will
be important to determine if these results using CD158b
mAb are applicable to responses to a natural ligand such as
HLA-Cw3 and to rationalize these results with the fact activating receptors have significantly lower affinity than inhibitory receptors (see Section 2.1.4).
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
653
5.3. Possible role of activating receptors
6. Expression of NK cell receptors
The purpose of inhibitory receptors with class I specificity on NK cells seems rather clear, but, as yet, it is not
so obvious why for each inhibitory receptor there is a corresponding activating receptor of similar specificity, albeit
apparently of significant lower affinity. If they have the
same ligand, and the inhibitory receptor has a significantly
higher affinity, inhibition of activation would presumably
prevail. Moreover, why would it be necessary to have activating receptors that recognize “normally” expressed class
I molecules? It has been proposed (Tomasello et al., 2000a)
that, by interacting with the same ligand, the activating
receptors might serve to recruit the Src tyrosine kinase
that phosphorylates the ITIMs in the inhibitory receptors. This seems unlikely since Ly49 inhibitory receptors
work properly in mice deficient of DAP12 (Bakker et al.,
2000). A more intriguing possibility is that KIR, Ly49,
and NKG2 activating receptors have a low affinity for intact classical MHC class I molecules because these are not
the prescribed ligands for these receptors. It is possible
that the activating receptors recognize: (1) MHC class I
type molecules associated with specific peptides, perhaps
related to some pathological condition(s), (2) MHC class
I type molecules like MICA/B expressed by cells under
stress, and yet to be identified, and/or (3) MHC class I
type molecules not encoded within the MHC that could
even be pathogen encoded. A good example supporting
the latter possibility is data (Daniels et al., 2001; Brown
et al., 2001) showing that the expression of the murine
Ly49H activating receptor correlates with resistance to the
MCMV infection. Results by Ryan et al. (2001) suggest
that Ly49H recognizes a viral encoded protein instead of
a classical MHC class I molecule. Thus, it is possible that
inhibitory receptors bind self-MHC to prevent autoimmunity, while the activating receptors might have evolved to
recognize bacterial or viral MHC class I like proteins or
unique pathogen-derived peptides presented by a classical
or nonclassical MHC class I molecule(s) (Lanier, 2001).
In this context, autoreactive CD4+ CD28− T cells with
cytolytic capabilities are expanded in patients with vasculitic rheumatoid arthritis (RA). These cells have been
shown to express the KIR2DS2 activating receptor, usually in the absence of KIR inhibitory receptors (Namekawa
et al., 2000). Expression of the KIR2DS2 gene was significantly increased in patients with rheumatoid vasculitis
compared with normal individuals and in patients with
RA but no vasculitis. Also, the distribution of HLA-C
allotypes, which are putative ligands for KIR2DS2, was
significantly different in patients with rheumatoid vasculitis in comparison with control individuals. These data
suggest that CD4+ CD28− T cells expressing KIR2DS2
receptors may regulate vascular damage in RA vasculitis through recognition of particular HLA-C ligands
(Yen et al., 2001) perhaps in complex with a particular
peptide.
The expression of most class I specific NK cell receptors
are clonally distributed. Each NK cell expresses at least one
inhibitory receptor specific for a self-MHC class I molecule,
and they may or may not express an activating receptor
(Valiante et al., 1997). NK cell receptors can also be expressed by subpopulations of human T cells. The molecular
mechanisms that regulate the clonally diverse expression of
NK cell receptors on NK and T cells are unknown. Unlike
the TCR, the expression of NK cell receptors is not dependent on gene recombination events, indicating that their expression is largely transcriptionally regulated.
6.1. Regulation of expression in NK cells
The mechanism that generates and selects for NK cell
receptor gene expression in humans is not well defined.
Activated NK cell populations and NK clones isolated from
single donors have been shown to display different patterns
of cytolytic activity against a panel of allogeneic cells, indicating that an NK cell repertoire exists (Moretta et al.,
1994). Receptors are clonally distributed and many NK
cells in an individual share the same repertoire of receptors
(Long, 1999). Work in the mouse indicates that the expression of NK cell inhibitory receptors involves a stochastic
process with the final repertoire shaped by educational
processes based on MHC class I molecules expressed by
the host (Lanier, 1998; Raulet et al., 2001). Once an NK
cell receptor gene is activated for transcription, KIR and
CD94/NKG2 receptor expression is stably maintained in
the clonal expansion of the cells in long-term NK clone
cultures (Moretta et al., 1990).
A recent study looking into human NK cell receptor
ontogeny made use of stem cells derived from umbilical
cord blood cells to show the developmental stages at which
CD94 and KIR receptor expression is acquired (Miller and
McCullar, 2001). Contact-dependent ligand stimulation afforded by stromal feeder cells, along with the presence
of IL-15 and IL-2 in the culture, were important for optimal NK cell differentiation leading to receptor expression.
When cultures were devoid of the stimulating cytokines or
contact with the feeder cells, the NK cell progeny were KIR
and CD94 receptor negative. From single progenitor cells,
NK cell receptor acquisition was shown to be polyclonal
for both CD94 and KIR. The frequency of CD94+ NK
cells was greater than KIR and CD94 expression occurred
earlier, as shown by the number of CD56+ /CD94+ cells in
cultures at different time points. Other studies have shown
similar results using stroma-free cultures of progenitor cells
(Jaleco et al., 1997; Yu et al., 1998; Muench et al., 2000).
However, experiments by Mingari et al. (1997) using thymic
precursors showed that IL-15 in the absence of stroma
cells provides an appropriate stimulus for the expression
of CD94/NKG2A, but not for KIR receptors in the maturing of NK cells. The dependency on stroma cell presence
654
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
for complete human NK cell differentiation and receptor
acquisition agrees with the development of Ly49 receptor
expression by mouse NK cells (Roth et al., 2000). These
studies agree on the importance of IL-15 for NK cell development and receptor acquisition; however, whether stromal
cells are also necessary needs to be resolved, especially
since IL-15 can be made by stroma and macrophages.
The co-expression of KIR and CD94/NKG2 inhibitory
molecules within the NK cell population is well established.
Although, at first hand, the expression of these two families of molecules appears to be somewhat redundant, their
combined presence appears to be advantageous to the host.
The NK cells expressing the CD94/NKG2A receptor utilize HLA-E as a sentinel to reflect the global status of
class I expression. Cells are deemed abnormal only if they
down-regulate synthesis of most, if not all, class I molecules.
While the elegance of this system is that it allows an invariant NK cell receptor to detect the expression of a highly
divergent group of class I genes, the loss in the expression
of individual class I molecules can be overlooked. Therefore, it seems that KIR genes in humans and Ly49 genes
in the mouse may have evolved subsequent to the NKG2A
gene family to monitor the loss of expression of single class
I molecules (Lanier, 1998; Long, 1999).
6.2. Regulation of expression on T cells
This topic has recently been reviewed by McMahon and
Raulet (2001). About 5% of human peripheral blood CD8+
T cells express KIR and/or CD94/NKG2 family members
(Mingari et al., 1996a; Speiser et al., 1999b). Both stimulatory and inhibitory KIRs are expressed (Andre et al.,
1999; Mandelboim et al., 1998) and, like NK cells, CD8+
T cells are clonally distinct in their receptor expression pattern (Uhrberg et al., 2001). KIR molecules expressed on T
cells can regulate effector functions such as cytokine release and target cell cytolysis (Mingari et al., 1998; Ugolini
and Vivier, 2000), as can CD94/NKG2A molecules (Noppen et al., 1998; Speiser et al., 1999a).
KIR and CD94/NKG2 are not detectably expressed by
naı̈ve CD8+ T cells or by thymocytes. KIR expression
is restricted to CD8+ T cells bearing a memory phenotype (Mingari et al., 1996b). It is not clear what leads to
the induction of KIR expression, perhaps stimulation by
particular types of antigen. T cells specific for tumors,
particularly melanomas (Speiser et al., 1999b; Huard and
Karlsson, 2000b), viral antigens (Noppen et al., 1998) or
self-antigens (Huard and Karlsson, 2000a) have been shown
to express KIRs. Despite these examples, the majority of
antigen specific CTLs do not express KIR. Unlike KIRs,
CD94/NKG2A is upregulated on CD8+ T cells under certain culture conditions. This was demonstrated by culturing
T cells with superantigen or anti-TCR Ab in the presence
of IL-15 and IL-10 (Mingari et al., 1998; Galiani et al.,
1999) or TGF- (Bertone et al., 1999). Recent data indi-
cates that CD94/NKG2A expression is not limited to CD8+
T cells. Romero et al. (2001) showed that in the presence of
TGF- and IL-10 CD3 activated CD4+ T cells can express
CD94/NKG2A. Coligation of the TCR and CD94/NKG2A
on these cells resulted in an inhibition of TNF␣ and IFN-␥
secretion suggesting that CD94/NKG2A may at times regulate CD4+ T cell responses. Thus, current data indicate that
KIR expression is restricted to specific conditions of activation, perhaps antigen regulated, whereas CD94/NKG2A
expression is more generalized.
A number of hypotheses have been put forward to explain why CD8+ T cells express NK receptors (McMahon
and Raulet, 2001). One possibility is that inhibitory KIR
expressed by mature CTLs are reactive with peripheral
self antigens as a means of preventing autoimmunity. This
could allow class I specific inhibitory receptors to prevent
destruction of normal cells while allowing lysis of tumor
cells that have down-regulated expression of a particular
class I allele (Ikeda et al., 1997). A second possibility is
that KIR+ CTL may arise from chronic stimulation. This
is supported by the fact that almost no CTL express KIR
during acute viral infections, but chronic viral infections
like CMV or HIV give rise to oligoclonal KIR+ CTL
populations (Mingari et al., 1996a). Obviously such KIR
expression would lead to a weakened host response to
chronic infection and could contribute to viral pathogenesis
(De Maria and Moretta, 2000). To reconcile this, it has
been suggested that inhibitory receptor expression provides
a mechanism for chronically stimulated CTLs to avoid
over-stimulation leading to activation-induced apoptosis.
Subsequent down modulation of KIR by surviving cells
may allow them to respond later to antigenic restimulation.
Indeed Huard and Karlsson (2000a) have shown that, in the
absence of antigen, KIR+ CTL down-regulate KIR expression to non-functional levels. Lastly it has been proposed
that inhibitory receptors, by preventing activation induced
apoptosis of CTL during immune response, may aid in the
formation of memory CTLs (Ugolini et al., 2001).
References
Algarra, I., Cabrera, T., Garrido, F., 2000. The HLA crossroad in tumor
immunology. Hum. Immunol. 61, 65–73.
Allan, D.S., Colonna, M., Lanier, L.L., Churakova, T.D., Abrams, J.S.,
Ellis, S.A., McMichael, A.J., Braud, V.M., 1999. Tetrameric complexes
of human histocompatibility leukocyte antigen (HLA)-G bind to
peripheral blood myelomonocytic cells. J. Exp. Med. 189, 1149–1156.
Andre, P., Brunet, C., Guia, S., Gallais, H., Stampol, J., Vivier, E.,
Dignat-George, F., 1999. Differential regulation of killer cell Ig-like
receptors and CD94 lectin-like dimmers on NK and T lymphocytes
fro HIV-1-infected individuals. Eur. J. Immunol. 29, 1076–1085.
Andre, P., Biassoni, R., Colonna, M., Cosman, D., Lanier, L.L., Long,
E.O., López-Botet, M., Moretta, A., Moretta, L., Parham, P., Trowsdale,
J., Vivier, E., Wagtmann, N., Wilson, M.J., 2001. New nomenclature
for MHC receptors. Nat. Immunol. 2, 661.
Arce, I., Roda-Navarro, P., Montoya, M.C., Hernanz-Falcon, P.,
Puig-Kroger, A., Fernandez-Ruiz, E., 2001. Molecular and genomic
characterization of human DLEC, a novel member of the C-type lectin
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
receptor gene family preferentially expressed on monocyte-derived
dendritic cells. Eur. J. Immunol. 31, 2733–2740.
Arnaiz-Villena, A., Martinez-Laso, J., Alvarez, M., Castro, M.J., Varela,
P., Gomez-Casado, E., Suarez, B., Recio, M.J., Vargas-Alarcon, G.,
Morales, P., 1997. Primate Mhc-E and -G alleles. Immunogenetics 46,
251–266.
Baba, E., Erskine, R., Boyson, J.E., Cohen, G.B., Davis, D.M., Malik,
P., Mandelboim, O., Reyburn, H.T., Strominger, J.L., 2000. N-linked
carbohydrate on human leukocyte antigen-C and recognition by natural
killer cell inhibitory receptors. Hum. Immunol. 61, 1202–1218.
Bahram, S., 2000. MIC genes: from genetics to biology. Adv. Immunol.
76, 1–60.
Bakker, A.B., Hoek, R.M., Cerwenka, A., Blom, B., Lucian, L., McNeil,
T., Murray, R., Phillips, L.H., Sedgwick, J.D., Lanier, L.L., 2000.
DAP12-deficient mice fail to develop autoimmunity due to impaired
antigen priming. Immunity 13, 345–353.
Barber, L.D., Percival, L., Valiante, N.M., Chen, L., Lee, C., Gumperz,
J.E., Phillips, J.H., Lanier, L.L., Bigge, J.C., Parekh, R.B., Parham, P.,
1996. The inter-locus recombinant HLA-B∗ 4601 has high selectivity
in peptide binding and functions characteristic of HLA-C. J. Exp. Med.
184, 735–740.
Barford, D., Neel, B.G., 1998. Revealing mechanisms for SH2 domain
mediated regulation of the protein tyrosine phosphatase SHP-2.
Structure 6, 249–254.
Barten, R., Trowsdale, J., 1999. The human Ly-49L gene. Immunogenetics
49, 731–734.
Barten, R., Torkar, M., Haude, A., Trowsdale, J., Wilson, M.J., 2001.
Divergent and convergent evolution of NK-cell receptors. Trends
Immunol. 22, 52–57.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L., Spies,
T., 1999. Activation of NK cells and T cells by NKG2D, a receptor
for stress-inducible MICA. Science 285, 727–729.
Bellon, T., Heredia, A.B., Llano, M., Minguela, A., Rodriguez, A.,
López-Botet, M., Aparicio, P., 1999. Triggering of effector functions on
a CD8+ T cell clone upon the aggregation of an activatory CD94/kp39
heterodimer. J. Immunol. 162, 3996–4002.
Bertone, S., Schiavetti, F., Bellomo, R., Vitale, C., Ponte, M., Moretta,
L., Mingari, M.C., 1999. Transforming growth factor-beta-induced
expression of CD94/NKG2A inhibitory receptors in human T
lymphocytes. Eur. J. Immunol. 29, 23–29.
Biassoni, R., Falco, M., Cambiaggi, A., Costa, P., Verdiani, S., Pende, D.,
Conte, R., Di Donato, C., Parham, P., Moretta, L., 1995. Amino acid
substitutions can influence the natural killer (NK)-mediated recognition
of HLA-C molecules. Role of serine-77 and lysine-80 in the target
cell protection from lysis mediated by group 2 or group 1 NK clones.
J. Exp. Med. 182, 605–609.
Biassoni, R., Cantoni, C., Falco, M., Verdiani, S., Bottino, C., Vitale,
M., Conte, R., Poggi, A., Moretta, A., Moretta, L., 1996. The human
leukocyte antigen (HLA)-C-specific activatory or inhibitory natural
killer cell receptors display highly homologous extracellular domains
but differ in their transmembrane and intracytoplasmic portions. J.
Exp. Med. 183, 645–650.
Biassoni, R., Pessino, A., Malaspina, A., Cantoni, C., Bottino, C., Sivori,
S., Moretta, L., Moretta, A., 1997. Role of amino acid position 70
in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4
molecules. Eur. J. Immunol. 27, 3095–3099.
Biassoni, R., Cantoni, C., Pende, D., Sivori, S., Parolini, S., Vitale, M.,
Bottino, C., Moretta, A., 2001. Human natural killer cell receptors and
co-receptors. Immunol. Rev. 181, 203–214.
Binstadt, B.A., Brumbaugh, K.M., Dick, C.J., Scharenberg, A.M.,
Williams, B.L., Colonna, M., Lanier, L.L., Kinet, J.P., Abraham, R.T.,
Leibson, P.J., 1996. Sequential involvement of Lck and SHP-1 with
MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine
kinase activation. Immunity 5, 629–638.
Binstadt, B.A., Billadeau, D.D., Jevremovic, D., Williams, B.L., Fang, N.,
Yi, T., Koretzky, G.A., Abraham, R.T., Leibson, P.J., 1998. SLP-76 is
a direct substrate of SHP-1 recruited to killer cell inhibitory receptors.
J. Biol. Chem. 273, 27518–27523.
655
Bléry, M., Olcese, L., Vivier, E., 2000. Early signaling via inhibitory and
activating NK receptors. Hum. Immunol. 61, 51–64.
Bonacci, G., Sanchez, M.C., Gonzalez, M., Ceschin, D., Fidelio, G.,
Vides, M.A., Chiabrando, G., 2000. Stabilization of homogeneous
preparations of pregnancy zone protein lyophilized in the presence
of saccharose: structural and functional studies. J. Biochem. Biophys.
Methods 46, 95–105.
Borges, L., Hsu, M.L., Fanger, N., Kubin, M., Cosman, D., 1997. A
family of human lymphoid and myeloid Ig-like receptors, some of
which bind to MHC class I molecules. J. Immunol. 159, 5192–5196.
Borrego, F., Ulbrecht, M., Weiss, E.H., Coligan, J.E., Brooks, A.G., 1998.
Recognition of human histocompatibility leukocyte antigen (HLA)-E
complexed with HLA class I signal sequence-derived peptides by
CD94/NKG2 confers protection from natural killer cell-mediated lysis.
J. Exp. Med. 187, 813–818.
Borrego, F., Robertson, M.J., Ritz, J., Pena, J., Solana, R., 1999. CD69
is a stimulatory receptor for natural killer cell and its cytotoxic effect
is blocked by CD94 inhibitory receptor. Immunology 97, 159–165.
Bottino, C., Falco, M., Parolini, S., Marcenaro, E., Augugliaro, R., Sivori,
S., Landi, E., Biassoni, R., Notarangelo, L.D., Moretta, L., Moretta, A.,
2001. Gntb-a, a novel sh2d1a-associated surface molecule contributing
to the inability of natural killer cells to kill epstein-barr virus-infected
b cells in x-linked lymphoproliferative disease. J. Exp. Med. 194, 235–
246.
Boyington, J.C., Riaz, A.N., Patamawenu, A., Coligan, J.E., Brooks, A.G.,
Sun, P.D., 1999. Structure of CD94 reveals a novel C-type lectin
fold: implications for the NK cell-associated CD94/NKG2 receptors.
Immunity 10, 75–82.
Boyington, J.C., Motyka, S.A., Schuck, P., Brooks, A.G., Sun, P.D.,
2000. Crystal structure of an NK cell immunoglobulin-like receptor in
complex with its class I MHC ligand. Nature 405, 537–543.
Boyington, J.C., Brooks, A.G., Sun, P.D., 2001. Structure of killer cell
immunoglobulin-like receptors and their recognition of the class I
MHC molecules. Immunol. Rev. 181, 66–78.
Braud, V., Jones, E.Y., McMichael, A., 1997. The human major
histocompatibility complex class Ib molecule HLA-E binds signal
sequence-derived peptides with primary anchor residues at positions 2
and 9. Eur. J. Immunol. 27, 1164–1169.
Braud, V.M., Allan, D.S., O’Callaghan, C.A., Soderstrom, K., D’Andrea,
A., Ogg, G.S., Lazetic, S., Young, N.T., Bell, J.I., Phillips, J.H.,
Lanier, L.L., McMichael, A.J., 1998. HLA-E binds to natural killer
cell receptors CD94/NKG2A, B and C. Nature 391, 795–799.
Brooks, A.G., Posch, P.E., Scorzelli, C.J., Borrego, F., Coligan, J.E., 1997.
NKG2A complexed with CD94 defines a novel inhibitory natural killer
cell receptor. J. Exp. Med. 185, 795–800.
Brooks, A.G., Borrego, F., Posch, P.E., Patamawenu, A., Scorzelli, C.J.,
Ulbrecht, M., Weiss, E.H., Coligan, J.E., 1999. Specific recognition
of HLA-E, but not classical, HLA class I molecules by soluble
CD94/NKG2A and NK cells. J. Immunol. 162, 305–313.
Brostjan, C., Sobanov, Y., Glienke, J., Hayer, S., Lehrach, H., Francis,
F., Hofer, E., 2000. The NKG2 natural killer cell receptor family:
comparative analysis of promoter sequences. Genes Immunol. 1, 504–
508.
Brown, M.G., Dokun, A.O., Heusel, J.W., Smith, H.R., Beckman,
D.L., Blattenberger, E.A., Dubbelde, C.E., Stone, L.R., Scalzo, A.A.,
Yokoyama, W.M., 2001. Vital involvement of a natural killer cell
activation receptor in resistance to viral infection. Science 292, 934–
937.
Bruhns, P., Marchetti, P., Fruidman, W.H., Vivier, E., Daëron, M., 1999.
Differential roles of N- and C-terminal ITIMs during inhibition of cell
activation by killer cell inhibitory receptors. J. Immunol. 162, 3168–
3175.
Burshtyn, D.N., Long, E.O., 1997. Regulation through inhibitory receptors:
lessons from natural killer cells. Trends. Cell Biol. 7, 473–479.
Burshtyn, D.N., Scharenberg, A.M., Wagtmann, N., Rajagopalan, S.,
Berrada, K., Yi, T., Kinet, J.P., Long, E.O., 1996. Recruitment of
tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity
4, 77–85.
656
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
Burshtyn, D.N., Yang, W., Yim, T., Long, E.O., 1997. A novel
phosphotyrosine motif with a critical amino acid at position -2 for the
SH2 domain-mediated activation of the tyrosine phosphatase SHP-1.
J. Biol. Chem. 272, 13066–13072.
Burshtyn, D.N., Lam, A.S., Weston, M., Gupta, N., Warmerdam, P.A.,
Long, E.O., 1999. Conserved residues amino-terminal of cytoplasmic
tyrosines contribute to the SHP-1-mediated inhibitory function of killer
cell Ig-like receptors. J. Immunol. 162, 897–902.
Campbell, K.S., Dessing, M., López-Botet, M., Cella, M., Colonna, M.,
1996. Tyrosine phosphorylation of a human killer inhibitory receptor
recruits protein tyrosine phosphatase 1C. J. Exp. Med. 184, 93–100.
Cantoni, C., Verdiani, S., Falco, M., Pessino, A., Cilli, M., Conte, R.,
Pende, D., Ponte, M., Mikaelsson, M.S., Moretta, L., Biassoni, R.,
1998. P49, a putative HLA class I-specific inhibitory NK receptor
belonging to the immunoglobulin superfamily. Eur. J. Immunol. 28,
1980–1990.
Carretero, M., Cantoni, C., Bellon, T., Bottino, C., Biassoni, R., Rodriguez,
A., Perez-Villar, J.J., Moretta, L., Moretta, A., López-Botet, M., 1997.
The CD94 and NKG2-A C-type lectins covalently assemble to form a
natural killer cell inhibitory receptor for HLA class I molecules. Eur.
J. Immunol. 27, 563–567.
Cerwenka, A., Lanier, L.L., 2001. Ligands for natural killer cell receptors:
redundancy or specificity. Immunol. Rev. 181, 158–169.
Cerwenka, A., Bakker, A.B., McClanahan, T., Wagner, J., Wu, J., Phillips,
J.H., Lanier, L.L., 2000. Retinoic acid early inducible genes define a
ligand family for the activating NKG2D receptor in mice. Immunity
12, 721–727.
Cerwenka, A., Baron, J.L., Lanier, L.L., 2001. Ectopic expression of
retinoic acid early inducible-1 gene (RAE-1) permits natural killer
cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc.
Natl. Acad. Sci. U.S.A. 98, 11521–11526.
Chapman, T.L., Heikeman, A.P., Bjorkman, P.J., 1999. The inhibitory
receptor LIR-1 uses a common binding interaction to recognize class I
MHC molecules and the viral homolog UL18. Immunity 11, 603–613.
Chapman, T.L., Heikema, A.P., West, A.P., Bjorkman, P.J., 2000. Crystal
structure and ligand binding properties of the D1D2 region of the
inhibitory receptor LIR-1 (ILT2). Immunity 13, 727–736.
Chuang, S.S., Pham, H.T., Kumaresan, P.R., Mathew, P.A., 2001. A
prominent role for activator protein-1 in the transcription of the human
2B4 (CD244) gene in NK cells. J. Immunol. 166, 6188–6195.
Cole, L.S., Diamond, P., Occhiodoro, F., Vadas, M.F., Shannon, M.A.,
1996. Cold Shock Domain proteins repress transcription of the
GM-CSF promoter. Nucl. Acids Res. 24, 2311–2317.
Colonna, M., Navarro, F., Bellon, T., Llano, M., Garcia, P., Samaridis, J.,
Angman, L., Cella, M., López-Botet, M., 1997. A common inhibitory
receptor for major histocompatibility complex class I molecules on
human lymphoid and myelomonocytic cells. J. Exp. Med. 186, 1809–
1818.
Colonna, M., Nakajima, H., Navarro, F., López-Botet, M., 1999. A novel
family of Ig-like receptors for HLA class I molecules that modulate
function of lymphoid and myeloid cells. J. Leukoc. Biol. 66, 375–381.
Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L.,
Hsu, M.L., 1997. A novel immunoglobulin superfamily receptor for
cellular and viral MHC class I molecules. Immunity 7, 273–282.
Cosman, D., Mullberg, J., Sutherland, C.L., Chin, W., Armitage, R.,
Fanslow, W., Kubin, M., Chalupny, N.J., 2001. ULBPs, novel MHC
class I-related molecules, bind to CMV glycoprotein UL16 and
stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14,
123–133.
D’Andrea, A., Chang, C., Phillips, J.H., Lanier, L.L., 1996. Regulation
of T cell lymphokine production by killer cell inhibitory receptor
recognition of self HLA class I alleles. J. Exp. Med. 184, 789–794.
Daniels, K.A., Devora, G., Lai, W.C., O’Donnell, C.L., Bennett, M.,
Welsh, R.M., 2001. Murine cytomegalovirus is regulated by a discrete
subset of natural killer cells reactive with monoclonal antibody to
Ly49H. J. Exp. Med. 194, 29–44.
Davis, D.M., Chiu, I., Fassett, M., Cohen, G.B., Mandelboim, O.,
Strominger, J.L., 1999. The human natural killer cell immune synapse.
Proc. Natl. Acad. Sci. U.S.A. 96, 5062–5067.
Day, A.J., 1994. The C-type carbohydrate recognition domain (CRD)
superfamily. Biochem. Soc. Trans. 22, 83–88.
De Maria, A., Moretta, L., 2000. HLA-class I-specific inhibitory receptors
in HIV-1 infection. Hum. Immunol. 61, 74–81.
Diefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N., Raulet, D.H.,
2000. Ligands for the murine NKG2D receptor: expression by tumor
cells and activation of NK cells and macrophages. Nat. Immunol. 1,
119–126.
Diefenbach, A., Jensen, E.R., Jamieson, A.M., Raulet, D.H., 2001. Rae1
and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Nature 413, 165–171.
Dustin, L.B., Plas, D.R., Wong, J., Hu, Y.T., Soto, C., Chan, A.C., Thomas,
M.L., 1999. Expression of dominant-negative src-homology domain
2-containing protein tyrosine phosphatase-1 results in increased Syk
tyrosine kinase activity and B cell activation. J. Immunol. 162, 2717–
2724.
Fan, Q.R., Mosyak, L., Winter, C.C., Wagtmann, N., Long, E.O., Wiley,
D.C., 1997. Structure of the inhibitory receptor for human natural killer
cells resembles haematopoietic receptors [published erratum appears
in Nature 390 (1997) 315]. Nature 389, 96–100.
Fan, Q.R., Long, E.O., Wiley, D.C., 2000. Cobalt-mediated dimerization
of the human natural killer cell inhibitory receptor. J. Biol. Chem. 275,
23700–23706.
Fan, Q.R., Long, E.O., Wiley, D.C., 2001. Crystal structure of the human
natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex.
Nat. Immunol. 2, 452–460.
Galiani, M.D., Aguado, E., Tarazona, R., Romero, P., Molina, I.,
Santamaria, M., Solana, R., Pena, J., 1999. Expression of killer
inhibitory receptors on cytotoxic cells from HIV-1-infected individuals.
Clin. Exp. Immunol. 115, 472–476.
Gergely, J., Pechet, I., Sarmay, G., 1999. Immunoreceptor tyrosine-based
inhibition motif-bearing receptors regulate the immunoreceptor
tyrosine-based activation motif-induced activation of immune
competent cells. Immunol. Lett. 68, 3–15.
Girardi, M., Oppenheim, D.E., Steele, C.R., Lewis, J.M., Glusac, E.,
Filler, R., Hobby, P., Sutton, B., Tigelaar, R.E., Hayday, A.C., 2001.
Regulation of cutaneous malignancy by gamma delta T Cells. Science
294, 605–609.
Glienke, J., Sobanov, Y., Brostjan, C., Steffens, C., Nguyen, C., Lehrach,
H., Hofer, E., Francis, F., 1998. The genomic organization of NKG2C,
E, F, and D receptor genes in the human natural killer gene complex.
Immunogenetics 48, 163–173.
Groh, V., Bahram, S., Bauer, S., Herman, A., Beauchamp, M., Spies, T.,
1996. Cell stress-regulated human major histocompatibility complex
class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad.
Sci. U.S.A. 93, 12445–12450.
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K.H., Spies,
T., 1999. Broad tumor-associated expression and recognition by
tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl.
Acad. Sci. U.S.A. 96, 6879–6884.
Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M.S., Riddell, S.R.,
Spies, T., 2001. Costimulation of CD8alphabeta T cells by NKG2D via
engagement by MIC induced on virus-infected cells. Nat. Immunol. 2,
255–260.
Gumperz, J.E., Litwin, V., Phillips, J.H., Lanier, L.L., Parham, P., 1995.
The Bw4 public epitope of HLA-B molecules confers reactivity with
natural killer cell clones that express NKB1, a putative HLA receptor.
J. Exp. Med. 181, 1133–1144.
Gumperz, J.E., Barber, L.D., Valiante, N.M., Percival, L., Phillips, J.H.,
Lanier, L.L., Parham, P., 1997. Conserved and variable residues within
the Bw4 motif of HLA-B make separable contributions to recognition
by the NKB1 killer cell-inhibitory receptor. J. Immunol. 158, 5237–
5241.
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
Hofer, E., Sobanov, Y., Brostjan, C., Lehrach, H., Duchler, M., 2001. The
centromeric part of the human natural killer (NK) receptor complex:
lectin-like receptor genes expressed in NK, dendritic and endothelial
cells. Immunol. Rev. 181, 5–19.
Houchins, J.P., Yabe, T., McSherry, C., Bach, F.H., 1991. DNA sequence
analysis of NKG2, a family of related cDNA clones encoding type II
integral membrane proteins on human natural killer cells. J. Exp. Med.
173, 1017–1020.
Huard, B., Karlsson, L., 2000a. KIR expression on self-reactive CD8+ T
cells is controlled by T-cell receptor engagement. Nature 403, 325–328.
Huard, B., Karlsson, L., 2000b. A subpopulation of CD8+ T cells specific
for melanocyte differentiation antigens expresses killer inhibitory
receptors (KIR) in healthy donors: evidence for a role of KIR in the
control of peripheral tolerance. Eur. J. Immunol. 30, 1665–1675.
Huyer, G., Alexander, D.R., 1999. Immune signalling: SHP-2 docks at
multiple ports. Curr. Biol. 25 (9), R129–R132.
Ikeda, H., Lethe, B., Lehmann, F., Van Baren, N., Baurain, J.F., De
Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., Coulie, P.,
1997. Characterization of an antigen that is recognized on a melanoma
showing partial HLA loss by CTL expressing an NK inhibitory receptor.
Immunity 6, 199–208.
Isakov, N., 1997. ITIMs and ITAMs. The Yin and Yang of antigen and
Fc receptor-linked signaling machinery. Immunol. Res. 16, 85–100.
Jaleco, A.C., Blom, B., Res, P., Weijer, K., Lanier, L.L., Phillips, J.H.,
Spits, H., 1997. Fetal liver contains committed NK progenitors, but is
not a site for development of CD34+ cells into T cells. J. Immunol.
159, 694–702.
Khakoo, S.I., Rajalingam, R., Shum, B.P., Weidenbach, K., Flodin,
L., Muir, D.G., Canavez, F., Cooper, S.L., Valiante, N.M., Lanier,
L.L., Parham, P., 2000. Rapid evolution of NK cell receptor systems
demonstrated by comparison of chimpanzees and humans. Immunity
12, 687–698.
Knapp, L.A., Cadavid, L.F., Watkins, D.I., 1998. The MHC-E locus is the
most well conserved of all known primate class I histocompatibility
genes. J. Immunol. 160, 189–196.
Kosugi, A., Sakakura, J., Yasuda, K., Ogata, M., Hamaoka, T., 2001.
Involvement of SHP-1 tyrosine phosphatase in TCR-mediated signaling
pathways in lipid rafts. Immunity 14, 669–680.
Kubin, M., Cassiano, L., Chalupny, J., Chin, W., Cosman, D., Fanslow,
W., Mullberg, J., Rousseau, A.M., Ulrich, D., Armitage, R., 2001.
ULBP1, 2, 3: novel MHC class I-related molecules that bind to
human cytomegalovirus glycoprotein UL16, activate NK cells. Eur. J.
Immunol. 31, 1428–1437.
Kumar, S., Hedges, S.B., 1998. A molecular timescale for vertebrate
evolution. Nature 392, 917–920.
Kwon, D., Chwae, Y.J., Choi, I.H., Park, J.H., Kim, S.J., Kim, J., 2000.
Diversity of the p70 killer cell inhibitory receptor (KIR3DL) family
members in a single individual. Mol. Cell 10, 54–60.
LaBonte, M.L., Levy, D.B., Letvin, N.L., 2000. Characterization of
rhesus monkey CD94/NKG2 family members and identification of
novel transmembrane-deleted forms of NKG2-A, B, C, and D.
Immunogenetics 51, 496–499.
Lanier, L.L., 1998. NK cell receptors. Annu. Rev. Immunol. 16, 359–393.
Lanier, L.L., 2001. Face off—the interplay between activating and
inhibitory immune receptors. Curr. Opin. Immunol. 13, 326–331.
Lanier, L.L., Corliss, B.C., Wu, J., Leong, C., Phillips, J.H., 1998a.
Immunoreceptor DAP12 bearing a tyrosine-based activation motif is
involved in activating NK cells. Nature 391, 703–707.
Lanier, L.L., Corliss, B., Wu, J., Phillips, J.H., 1998b. Association of
DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8,
693–701.
Lazetic, S., Chang, C., Houchins, J.P., Lanier, L.L., Phillips, J.H., 1996.
Human natural killer cell receptors involved in MHC class I recognition
are disulfide-linked heterodimers of CD94 and NKG2 subunits. J.
Immunol. 157, 4741–4745.
Le Drean, E., Vely, F., Olcese, L., Cambiaggi, A., Guia, S., Krystal,
G., Gervois, N., Moretta, A., Jotereau, F., Vivier, E., 1998. Inhibition
657
of antigen-induced T cell response and antibody-induced NK cell
cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2
protein-tyrosine phosphatases. Eur. J. Immunol. 28, 264–276.
Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., López-Botet,
M., Geraghty, D.E., 1998. HLA-E is a major ligand for the natural
killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. U.S.A.
95, 5199–5204.
Leibson, P.J., 1997. Signal transduction during natural killer cell activation:
inside the mind of a killer. Immunity 6, 655–661.
Lepin, E.J., Bastin, J.M., Allan, D.S., Roncador, G., Braud, V.M., Mason,
D.Y., van der Merwe, P.A., McMichael, A.J., Bell, J.I., Powis, S.H.,
O’Callaghan, C.A., 2000. Functional characterization of HLA-F and
binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur. J.
Immunol. 30, 3552–3561.
Li, P., Willie, S.T., Bauer, S., D, L., Spies, T., Strong, R.K., 1999. Crystal
structure of the MHC class I homolog MIC-A, a gammadelta T cell
ligand. Immunity 10, 577–584.
Li, P., Morris, D.L., Willcox, B.E., Steinle, A., Spies, T., Strong, R.K.,
2001. Complex structure of the activating immunoreceptor NKG2D
and its MHC class I-like ligand MICA. Nat. Immunol. 2, 443–451.
Ljunggren, H.G., Karre, K., 1990. In search of the missing self: MHC
molecules and NK cell recognition. Immunol. Today 11, 237–244.
Llano, M., Lee, N., Navarro, F., Garcia, P., Albar, J.P., Geraghty, D.E.,
López-Botet, M., 1998. HLA-E-bound peptides influence recognition
by inhibitory and triggering CD94/NKG2 receptors: preferential
response to an HLA-G-derived nonamer. Eur. J. Immunol. 28, 2854–
2863.
Long, E.O., 1999. Regulation of immune responses through inhibitory
receptors. Annu. Rev. Immunol. 17, 875–904.
Long, E.O., Barber, D.F., Burshtyn, D.N., Faure, M., Peterson, M.,
Rajagopalan, S., Renard, V., Sandusky, M., Stebbins, C.C., Wagtmann,
N., Watzl, C., 2001. Inhibition of natural killer cell activation signals
by killer cell immunoglobulin-like receptors (CD158). Immunol. Rev.
181, 223–233.
López-Botet, M., Bellon, T., 1999. Natural killer cell activation and
inhibition by receptors for MHC class I. Curr. Opin. Immunol. 11,
301–307.
López-Botet, M., Llano, M., Navarro, F., Bellon, T., 2000. NK cell
recognition of non-classical HLA class I molecules. Semin. Immunol.
12, 109–119.
Lorenz, U., Ravichandran, K.S., Burakoff, S.J., Neel, B.G., 1996. Lack
of SHPTP1 results in src-family kinase hyperactivation and thymocyte
hyperresponsiveness. Proc. Natl. Acad. Sci. U.S.A. 93, 9624–9629.
Lou, Z., Jevremovic, D., Billadeau, D.D., Leibson, P.J., 2000. A balance
between positive and negative signals in cytotoxic lymphocytes
regulates the polarization of lipid rafts during the development of
cell-mediated killing. J. Exp. Med. 191, 347–354.
Madueno, J.A., Muno, E., Blazquez, V., Gonzalez, R., Aparicio, P.,
Pena, J., 1993. The CD26 antigen is coupled to protein tyrosine
phosphorylation and implicated in CD16-mediated lysis in natural killer
cells. Scand. J. Immunol. 37, 425–429.
Maenaka, K., Juji, T., Nakayama, T., Wyer, J.R., Gao, G.F., Maenaka,
T., Zaccai, N.R., Kikuchi, A., Yabe, T., Tokunaga, K., Tadokoro, K.,
Stuart, D.I., Jones, E.Y., van der Merwe, P.A., 1999a. Killer cell
immunoglobulin receptors and T cell receptors bind peptide-major
histocompatibility complex class I with distinct thermodynamic and
kinetic properties. J. Biol. Chem. 274, 28329–28334.
Maenaka, K., Juji, T., Stuart, D.I., Jones, E.Y., 1999b. Crystal structure
of the human p58 killer cell inhibitory receptor (KIR2DL3) specific
for HLA-Cw3-related MHC class I. Structure Fold Des. 7, 391–398.
Mager, D.L., McQueen, K.L., Wee, V., Freeman, J.D., 2001. Evolution of
natural killer cell receptors: coexistence of functional Ly49 and KIR
genes in baboons. Curr. Biol. 11, 626–630.
Malnati, M.S., Peruzzi, M., Parker, K.C., Biddison, W.E., Ciccone, E.,
Moretta, A., Long, E.O., 1995. Peptide specificity in the recognition
of MHC class I by natural killer cell clones. Science 267, 1016–1018.
658
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
Mandelboim, O., Kent, S., Davis, D.M., Wilson, S.B., Okazaki, T.,
Jackson, R., Hafler, D., Strominger, J.L., 1998. Natural killer activating
receptors trigger interferon gamma secretion from T cells and natural
killer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 3798–3803.
Mandelboim, O., Lieberman, N., Lev, M., Paul, L., Arnon, T.I., Bushkin,
Y., Davis, D.M., Strominger, J.L., Yewdell, J.W., Porgador, A., 2001.
Recognition of haemagglutinins on virus-infected cells by NKp46
activates lysis by human NK cells. Nature 409, 1055–1060.
McMahon, C.W., Raulet, D.H., 2001. Expression and function of NK cell
receptors in CD8(+) T cells. Curr. Opin. Immunol. 13, 465–470.
Miller, J.S., McCullar, V., 2001. Human natural killer cells with
polyclonal lectin and immunoglobulinlike receptors develop from single
hematopoietic stem cells with preferential expression of NKG2A and
KIR2DL2/L3/S2. Blood 98, 705–713.
Mingari, M.C., Schiavetti, F., Ponte, M., Vitale, C., Maggi, E., Romagnani,
S., Demarest, J., Pantaleo, G., Fauch, A.S., Moretta, L., 1996a.
Human CD8+ T lymphocyte subsets that express HLA class I-specific
inhibitory receptors represent oligoclonally or monoclonally expanded
cell populations. Proc. Natl. Acad. Sci. U.S.A. 93, 12433–12438.
Mingari, M.C., Vitale, C., Schiavetti, F., Cambiaggi, A., Bertone, S.,
Zunino, A., Ponte, M., 1996b. HLA-class I-specific inhibitory receptors
of NK type on a subset of human T cells. Chem. Immunol. 64, 135–
145.
Mingari, M.C., Vitale, C., Cantoni, C., Bellomo, R., Ponte, M., Schiavetti,
F., Bertone, S., Moretta, A., Moretta, L., 1997. Interleukin-15-induced
maturation of human natural killer cells from early thymic precursors:
selective expression of CD94/NKG2-A as the only HLA class I-specific
inhibitory receptor. Eur. J. Immunol. 27, 1374–1380.
Mingari, M.C., Ponte, M., Bertone, S., Schiavetti, F., Vitale, C., Bellomo,
R., Moretta, A., Moretta, L., 1998. HLA class I-specific inhibitory
receptors in human T lymphocytes: interleukin 15-induced expression
of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T
cells. Proc. Natl. Acad. Sci. U.S.A. 95, 1172–1177.
Mizuki, N., Ota, M., Kimura, M., Ohno, S., Ando, H., Katsuyama, Y.,
Yamazaki, M., Watanabe, K., Goto, K., Nakamura, S., Bahram, S.,
Inoko, H., 1997. Triplet repeat polymorphism in the transmembrane
region of the MICA gene: a strong association of six GCT repetitions
with Behcet disease. Proc. Natl. Acad. Sci. U.S.A. 94, 1298–1303.
Moretta, A., Bottino, C., Pende, D., Tripodi, G., Tambussi, G., Viale, O.,
Orengo, A., Barbaresi, M., Merli, A., Ciccone, E., Moretta, M., 1990.
Identification of four subsets of human CD3-CD16+ natural killer
(NK) cells by the expression of clonally distributed functional surface
molecules: correlation between subset assignment of NK clones and
ability to mediate specific alloantigen recognition. J. Exp. Med. 172,
1589–1598.
Moretta, A., Sivori, S., Vitale, M., Pende, D., Morell, L., Augugliaro,
R., Bottino, C., Moretta, L., 1995. Existence of both inhibitory (p58)
and activatory (p50) receptors for HLA-C molecules in human natural
killer cells. J. Exp. Med. 182, 875–884.
Moretta, A., Moretta, L., 1997. HLA class I specific inhibitory receptors.
Curr. Opin. Immunol. 9, 694–701.
Moretta, L., Ciccone, E., Poggi, A., Mingari, M.C., Moretta, A., 1994.
Ontogeny, specific functions and receptors of human natural killer
cells. Immunol. Lett. 40, 83–88.
Moretta, L., Mingari, M.C., Pende, D., Bottino, C., Biassoni, R., Moretta,
A., 1996. The molecular basis of natural killer (NK) cell recognition
and function. J. Clin. Immunol. 16, 243–253.
Moretta, L., Biassoni, R., Bottino, C., Mingari, M.C., Moretta, A., 2000.
Human NK-cell receptors. Immunol. Today 21, 420–422.
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M.C.,
Biassoni, R., Moretta, L., 2001. Activating receptors and coreceptors
involved in human natural killer cell-mediated cytolysis. Annu. Rev.
Immunol. 19, 197–223.
Muench, M.O., Humeau, L., Paek, B., Ohkubo, T., Lanier, L.L.,
Albanese, C.T., Barcena, A., 2000. Differential effects of interleukin-3,
interleukin-7, interleukin 15, and granulocyte-macrophage colonystimulating factor in the generation of natural killer and B cells from
primitive human fetal liver progenitors. Exp. Hematol. 28, 961–973.
Nakajima, H., Colonna, M., 2000. 2B4: an NK cell activating receptor with
unique specificity and signal transduction mechanism. Hum. Immunol.
61, 39–43.
Nakajima, H., Cella, M., Langen, H., Friedlein, A., Colonna, M., 1999.
Activating interactions in human NK cell recognition: the role of
2B4-CD48. Eur. J. Immunol. 29, 1676–1683.
Nakamura, T., Takahashi, K., Koyanagi, M., Yagita, H., Okumura, K.,
1991. Activation of a natural killer clone upon target cell binding via
CD2. Eur. J. Immunol. 21, 831–834.
Namekawa, T., Snyder, M.R., Yen, J.H., Goehring, B.E., Leibson, P.J.,
Weyand, C.M., Goronzy, J.J., 2000. Killer cell activating receptors
function as costimulatory molecules on CD4+CD28null T cells
clonally expanded in rheumatoid arthritis. J. Immunol. 165, 1138–1145.
Navarro, F., Llano, M., Bellon, T., Colonna, M., Geraghty, D.E.,
López-Botet, M., 1999. The ILT2 (LIR1) and CD94/NKG2A NK
cell receptors respectively recognize HLA-G1 and HLA-E molecules
co-expressed on target cells. Eur. J. Immunol. 29, 277–283.
Noppen, C., Schaefer, C., Zajac, P., Schûtz, A., Kocher, T., Kloth, J.,
Heberer, M., Colonna, M., De Libero, G., Spagnoli, G.C., 1998.
C-type lectin-like receptors in peptide-specific HLA class I-restricted
cytotoxic T lymphocytes differential expression and modulation of
effector functions in clones sharing identical TCR structure and epitope
specificity. Eur. J. Immunol. 28, 1134–1142.
O’Callaghan, C.A., Cerwenka, A., Willcox, B.E., Lanier, L.L., Bjorkman,
P.J., 2001. Molecular competition for NKG2D: H60 and RAE1 compete
unequally for NKG2D with dominance of H60. Immunity 15, 201–211.
Olcese, L., Lange, P., Vély, F., Cambiaggi, A., Marquet, D., Blery, M.,
Hippen, K.L., Biassoni, R., Moretta, A., Moretta, L., Cambier, J.C.,
Vivier, E., 1996. Human and mouse killer-cell inhibitory receptors
recruit PTPIC and PTPID protein tyrosine phosphatases. J. Immunol.
156, 4531–4534.
Olcese, L., Cambiaggi, A., Semenzato, G., Bottino, C., Moretta, A.,
Vivier, E., 1997. Human killer cell activatory receptors for MHC class
I molecules are included in a multimeric complex expressed by natural
killer cells. J. Immunol. 158, 5083–5086.
Ono, M., Okada, H., Bolland, S., Yanagi, S., Kurosaki, T., Ravetch, J.V.,
1997. Deletion of SHIP or SHP-1 reveals two distinct pathways for
inhibitory signaling. Cell 90, 293–301.
Paloneva, J., Kestila, M., Wu, J., Salminen, A., Bohling, T., Ruotsalainen,
V., Hakola, P., Bakker, A.B., Phillips, J.H., Pekkarinen, P., Lanier,
L.L., Timonen, T., Peltonen, L., 2000. Loss-of-function mutations in
TYROBP (DAP12) result in a pre-senile dementia with bone cysts.
Nat. Genet. 25, 357–361.
Pei, D., Wang, J., Walsh, C.T., 1996. Differential functions of the two
Src homology 2 domains in protein tyrosine phosphatase SH-PTP1.
Proc. Natl. Acad. Sci. U.S.A. 93, 1141–1145.
Pende, D., Biassoni, R., Cantoni, C., Verdiani, S., Falco, M., di Donato,
C., Accame, L., Bottino, C., Moretta, A., Moretta, L., 1996. The natural
killer cell receptor specific for HLA-A allotypes: a novel member of
the p58/p70 family of inhibitory receptors that is characterized by
three immunoglobulin-like domains and is expressed as a 140 kDa
disulphide-linked dimer. J. Exp. Med. 184, 505–518.
Pende, D., Cantoni, C., Rivera, P., Vitale, M., Castriconi, R., Marcenaro,
S., Nannin, M., Biassoni, R., Bottino, C., Moretta, A., Moretta, L.,
2001. Role of NKG2D in tumor cell lysis mediated by human NK
cells: cooperation with natural cytotoxicity receptors and capability
of recognizing tumors of nonepithelial origin. Eur. J. Immunol. 31,
1076–1086.
Perez-Villar, J.J., Melero, I., Gismondi, A., Santoni, A., López-Botet, M.,
1996. Functional analysis of alpha 1 beta 1 integrin in human natural
killer cells. Eur. J. Immunol. 26, 2023–2029.
Peruzzi, M., Parker, K.C., Long, E.O., Malnati, M.S., 1996a. Peptide
sequence requirements for the recognition of HLA-B∗ 2705 by specific
natural killer cells. J. Immunol. 157, 3350–3356.
Peruzzi, M., Wagtmann, N., Long, E.O., 1996b. A p70 killer cell inhibitory
receptor specific for several HLA-B allotypes discriminates among
peptides bound to HLA-B∗ 2705. J. Exp. Med. 184, 1585–1590.
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
Peterson, E.J., Clements, J.L., Ballas, Z.K., Koretzky, G.A., 1999. NK
cytokine secretion and cytotoxicity occur independently of the SLP-76
adaptor protein. Eur. J. Immunol. 29, 2223–2232.
Plas, D.R., Johnson, R., Pingel, J.T., Matthews, R.J., Dalton, M., Roy,
G., Chan, A.C., Thomas, M.L., 1996. Direct regulation of ZAP-70 by
SHP-1 in T cell antigen receptor signaling. Science 272, 1173–1176.
Ploegh, H.L., 1998. Viral strategies of immune evasion. Science 280,
248–253.
Plougastel, B., Trowsdale, J., 1997. Cloning of NKG2-F, a new member
of the NKG2 family of human natural killer cell receptor genes. Eur.
J. Immunol. 27, 2835–2839.
Plougastel, B., Trowsdale, J., 1998. Sequence analysis of a 62 kb region
overlapping the human KLRC cluster of genes. Genomics 49, 193–199.
Pluskey, S., Wandless, T.J., Walsh, C.T., Shoelson, S.E., 1995.
Potent stimulation of SH-PTP2 phosphatase activity by simultaneous
occupancy of both SH2 domains. J. Biol. Chem. 270, 2897–2900.
Ponte, M., Cantoni, C., Biassoni, R., Tradori-Cappai, A., Bentivoglio,
G., Vitale, C., Bertone, S., Moretta, A., Moretta, L., Mingari,
M.C., 1999. Inhibitory receptors sensing HLA-G1 molecules in
pregnancy: decidua-associated natural killer cells express LIR-1 and
CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc.
Natl. Acad. Sci. U.S.A. 96, 5674–5679.
Posch, P.E., Borrego, F., Brooks, A.G., Coligan, J.E., 1998. HLA-E is the
ligand for the natural killer cell CD94/NKG2 receptors. J. Biomed.
Sci. 5, 321–331.
Qu, C.K., Yu, W.M., Azzarelli, B., Feng, G.S., 1999. Genetic evidence
that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal
growth factor receptor in mammals. Proc. Natl. Acad. Sci. U.S.A. 96,
8528–8533.
Rajagopalan, S., Long, E.O., 1997. The direct binding of a p58 killer
cell inhibitory receptor to human histocompatibility leukocyte antigen
(HLA)-Cw4 exhibits peptide selectivity. J. Exp. Med. 185, 1523–1528.
Rajagopalan, S., Long, E.O., 1998. Zinc bound to the killer cell-inhibitory
receptor modulates the negative signal in human NK cells. J. Immunol.
161, 1299–1305.
Rajagopalan, S., Long, E.O., 1999. A human histocompatibility leukocyte
antigen (HLA)-G-specific receptor expressed on all natural killer cells
[Published erratum appears in J. Exp. Med. 191 (2000) 2027]. J. Exp.
Med. 189, 1093–1100.
Rajagopalan, S., Winter, C.C., Wagtmann, N., Long, E.O., 1995. The
Ig-related killer cell inhibitory receptor binds zinc and requires zinc for
recognition of HLA-C on target cells. J. Immunol. 155, 4143–4146.
Rajagopalan, S., Fu, J., Long, E.O., 2001. Induction of IFN-␥ production
but not cytotoxicicty by the killer cell Ig-like receptor KIR2DL4
(CD158d) in resting NK cells. J. Immunol. 167, 1877–1881.
Raulet, D.H., Vance, R.E., McMahon, C.W., 2001. Regulation of the
natural killer cell receptor repertoire. Annu. Rev. Immunol. 19, 291–
330.
Ravetch, J.V., Lanier, L.L., 2000. Immune inhibitory receptors. Science
290, 84–89.
Renedo, M., Arce, I., Montgomery, K., Roda-Navarro, P., Lee, E.,
Kucherlapati, R., Fernandez-Ruiz, E., 2000. A sequence-ready physical
map of the region containing the human natural killer gene complex
on chromosome 12p12.3–p13.2. Genomics 65, 129–136.
Roda-Navarro, P., Arce, I., Renedo, M., Montgomery, K., Kucherlapati,
R., Fernandez-Ruiz, E., 2000. Human KLRF1, a novel member of the
killer cell lectin-like receptor gene family: molecular characterization,
genomic structure, physical mapping to the NK gene complex and
expression analysis. Eur. J. Immunol. 30, 568–576.
Rodriguez, A., Carretero, M., Glienke, J., Bellon, T., Ramirez, A., Lehrach,
H., Francis, F., López-Botet, M., 1998. Structure of the human CD94
C-type lectin gene. Immunogenetics 47, 305–309.
Rojo, S., Wagtmann, N., Long, E.O., 1997. Binding of a soluble p70 killer
cell inhibitory receptor to HLA-B∗ 5101: requirement for all three p70
immunoglobulin domains. Eur. J. Immunol. 27, 568–571.
Romero, P., Ortega, C., Palma, A., Molina, I.J., Pena, J., Santamaria, M.,
2001. Expression of CD94 and NKG2 molecules on human CD4(+)
659
T cells in response to CD3-mediated stimulation. J. Leukoc. Biol. 70,
219–224.
Roth, C., Carlyle, J.R., Takizawa, H., Raulet, D.H., 2000. Clonal
acquisition of inhibitory Ly49 receptors on developing NK cells is
successively restricted and regulated by stromal class I MHC. Immunity
13, 143–153.
Ryan, J.C., Naper, C., Hayashi, S., Daws, M.R., 2001. Physiologic
functions of activating natural killer (NK) complex-encoded receptors
on NK cells. Immunol. Rev. 181, 126–137.
Samaridis, J., Colonna, M., 1997. Cloning of novel immunoglobulin
superfamily receptors expressed on human myeloid and lymphoid cells:
structural evidence for new stimulatory and inhibitory pathways. Eur.
J. Immunol. 27, 660–665.
Saverino, D., Fabbi, M., Ghiotto, F., Merlo, A., Bruno, S., Zarcone, D.,
Tenca, C., Tiso, M., Santoro, G., Anastasi, G., Cosman, D., Grossi,
C.E., Ciccone, E., 2000. The CD85/LIR-1/ILT2 inhibitory receptor
is expressed by all human T lymphocytes and down-regulates their
functions. J. Immunol. 165, 3742–3755.
Selvakumar, A., Steffens, U., Dupont, B., 1996. NK cell receptor gene
of the KIR family with two IG domains but highest homology to KIR
receptors with three IG domains. Tissue Antigens 48, 285–294.
Selvakumar, A., Steffens, U., Dupont, B., 1997. Polymorphism and domain
variability of human killer cell inhibitory receptors. Immunol. Rev.
155, 183–196.
Shilling, H.G., Lienert-Weidenbach, K., Valiante, N.M., Uhrberg, M.,
Parham, P., 1998. Evidence for recombination as a mechanism for KIR
diversification. Immunogenetics 48, 413–416.
Shlapatska, L.M., Mikhalap, S.V., Berdova, A.G., Zelensky, O.M., Yun,
T.J., Nichols, K.E., Clark, E.A., Sidorenko, S.P., 2001. CD150
association with either the SH2-containing inositol phosphatase or
the SH2-containing protein tyrosine phosphatase is regulated by the
adaptor protein SH2D1A. J. Immunol. 166, 5480–5487.
Snyder, G.A., Brooks, A.G., Sun, P.D., 1999. Crystal structure of the
HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2.
Proc. Natl. Acad. Sci. U.S.A. 96, 3864–3869.
Sobanov, V., Gleinke, J., Brostjan, C., Lehrach, H.F., Hofer, E., 1999.
Linkage of the NKG2 and CD94 receptor genes to D12S77 in the
human natural killer gene complex. Immunogenetics 49, 99–105.
Speiser, D.E., Valmori, D., Rimoldi, D., Pittet, M.J., Lienard, D.,
Cerundolo, V., MacDonald, H.R., Cerottini, J.C., Romero, P., 1999a.
CD28-negative cytolytic effector T cells frequently express NK
receptors and are present at variable proportions in circulating
lymphocytes fro healthy donors and melanoma patients. Eur. J.
Immunol. 29, 1990–1999.
Speiser, D.E., Valmori, D., Rimoldi, D., Pittet, M.J., Lienard, D.,
Cerundolo, V., MacDonald, H.R., Cerottini, J.C., Romero, P., 1999b.
In vivo expression of natural killer cell inhibitory receptors by human
melanoma-specific cytolytic T lymphocytes. J. Exp. Med. 190, 775–
782.
Stahls, A., Heiskala, M., Mustelin, T., Andersson, L.C., 1992. Activation
of natural killer cells via the Fc gamma RIII (CD16) requires initial
tyrosine phosphorylation. Eur. J. Immunol. 22, 611–614.
Steinle, A., Li, P., Morris, D.L., Groh, V., Lanier, L.L., Strong, R.K., Spies,
T., 2001. Interactions of human NKG2D with its ligands MICA, MICB,
and homologs of the mouse RAE-1 protein family. Immunogenetics
53, 279–287.
Sunder-Plassmann, R., Lialios, F., Madsen, M., Koyasu, S., Reinherz,
E.L., 1997. Functional analysis of immunoreceptor tyrosine-based
activation motif (ITAM)-mediated signal transduction: the two YxxL
segments within a single CD3zeta-ITAM are functionally distinct. Eur.
J. Immunol. 27, 2001–2009.
Thompson, C.B., Allison, J.P., 1997. The emerging role of CTLA-4 as
an immune attenuator. Immunity 7, 445–450.
Tomasello, E., Blery, M., Vely, E., Vivier, E., 2000a. Signaling pathways
engaged by NK cell receptors: double concerto for activating receptors,
inhibitory receptors and NK cells. Semin. Immunol. 12, 139–147.
660
F. Borrego et al. / Molecular Immunology 38 (2001) 637–660
Tomasello, E., Desmoulins, P.O., Chemin, K., Guia, S., Cremer, H.,
Ortaldo, J., Love, P., Kaiserlian, D., Vivier, E., 2000b. Combined natural
killer cell and dendritic cell functional deficiency in KARAP/DAP12
loss-of-function mutant mice. Immunity 13, 355–364.
Ugolini, S., Vivier, E., 2000. Regulation of T cell function by NK cell
receptors for classical MHC class I molecules. Curr. Opin. Immunol.
12, 295–300.
Ugolini, S., Arpin, C., Anfossi, N., Walzer, T., Cambiaggi, A., Forster,
R., Lipp, M., Toes, R.E., Melief, C.J., Marvel, J., Vivier, E., 2001.
Involvement of inhibitory NKRs in the survival of a subset of
memory-phenotype CD8+ T cells. Nat. Immunol. 2, 430–435.
Uhrberg,
M.,
Valiante, N.M., Shum, B.P., Shilling, H.G., Lienert-Weidenbach, K.,
Corliss, B., Tyan, D., Lanier, L.L., Parham, P., 1997. Human diversity
in killer cell inhibitory receptor genes. Immunity 7, 753–763.
Uhrberg, M., Valiante, N.M., Young, N.T., Lanier, L.L., Phillips, J.H.,
Parham, P., 2001. The repertoire of killer cell Ig-like receptor and
CD94:NKG2A receptors in T cells: clones sharing identical alpha beta
TCR rearrangement express highly diverse killer cell Ig-like receptor
patterns. J. Immunol. 166, 3923–3932.
Ulbrecht, M., Modrow, S., Srivastava, R., Peterson, P.A., Weiss, E.H.,
1998. Interaction of HLA-E with peptides and the peptide transporter in
vitro: implications for its function in antigen presentation. J. Immunol.
160, 4375–4385.
Vales-Gomez, M., Reyburn, H.T., Erskine, R.A., Strominger, J., 1998a.
Differential binding to HLA-C of p50-activating and p58-inhibitory
natural killer cell receptors. Proc. Natl. Aca. Sci. U.S.A. 95, 14326–
14331.
Vales-Gomez, M., Reyburn, H.T., Mandelboim, M., Strominger, J.L.,
1998b. Kinetics of interaction of HLA-C ligands with natural killer
cell inhibitory receptors [published erratum appears in Immunity 9
(1998) 892]. Immunity 9, 337–344.
Vales-Gomez, M., Reyburn, H.T., Erskine, R.A., López-Botet, M.,
Strominger, J.L., 1999. Kinetics and peptide dependency of the binding
of the inhibitory NK receptor CD94/NKG2-A and the activating
receptor CD94/NKG2-C to HLA-E. EMBO J. 18, 4250–4260.
Vales-Gomez, M., Erskine, R.A., Deacon, M.P., Strominger, J.L., Reyburn,
H.T., 2001. The role of zinc in the binding of killer cell Ig-like receptors
to class I MHC proteins. Proc. Natl. Acad. Sci. U.S.A. 98, 1734–1739.
Valiante, N.M., Phillips, J.H., Lanier, L.L., Parham, P., 1996. Killer cell
inhibitory receptor recognition of human leukocyte antigen (HLA)
class I blocks formation of a pp36/PLC-gamma signaling complex in
human natural killer (NK) cells. J. Exp. Med. 184, 2243–2250.
Valiante, N.M., Uhrberg, M., Shilling, H.G., Lienert-Weidenbach, K.,
Arnett, K.L., D’Andrea, A., Phillips, J.H., Lanier, L.L., Parham, P.,
1997. Functionally and structurally distinct NK cell receptor repertoires
in the peripheral blood of two human donors. Immunity 7, 739–751.
Vely, F., Olivero, S., Olcese, L., Moretta, A., Damen, J.E., Liu, L.,
Krystal, G., Cambier, J.C., Daeron, M., Vivier, E., 1997. Differential
association of phosphatases with hematopoietic co-receptors bearing
immunoreceptor tyrosine-based inhibition motifs. Eur. J. Immunol. 27,
1994–2000.
Vilches, C., Gardiner, C.M., Parham, P., 2000a. Gene structure and
promoter variation of expressed and nonexpressed variants of the
KIR2DL5 gene. J. Immunol. 165, 6416–6421.
Vilches, C., Rajalingam, R., Uhrberg, M., Gardiner, C.M., Young, N.T.,
Parham, P., 2000b. KIR2DL5, a novel killer-cell receptor with a D0–D2
configuration of Ig-like domains. J. Immunol. 164, 5797–5804.
Vitale, M., Castriconi, R., Parolini, S., Pende, D., Hsu, M.L., Moretta, L.,
Cosman, D., Moretta, A., 1999. The leukocyte Ig-like receptor (LIR)-1
for the cytomegalovirus UL18 protein displays a broad specificity for
different HLA class I alleles: analysis of LIR-1 + NK cell clones. Int.
Immunol. 11, 29–35.
Vitale, M., Falco, M., Castriconi, R., Parolini, S., Zambello, R., Semenzato,
G., Biassoni, R., Bottino, C., Moretta, L., Moretta, A., 2001.
Identification of NKp80, a novel triggering molecule expressed by
human NK cells. Eur. J. Immunol. 31, 233–242.
Vivier, E., Daeron, M., 1997. Immunoreceptor tyrosine-based inhibition
motifs. Immunol. Today 18, 286–291.
Vivier, E., Morin, P., O’Brien, C., Druker, B., Schlossman, S.F., Anderson,
P., 1991a. Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta
complex in human natural killer cells. Induction by antibody-dependent
cytotoxicity but not by natural killing. J. Immunol. 146, 206–210.
Vivier, E., Morin, P.M., O’Brien, C., Schlossman, S.F., Anderson, P.,
1991b. CD2 is functionally linked to the zeta-natural killer receptor
complex. Eur. J. Immunol. 21, 1077–1080.
Wagtmann, N., Rojo, S., Eichler, E., Mohrenweiser, H., Long, E.O., 1997.
A new human gene complex encoding the killer cell inhibitory receptors
and related monocyte/macrophage receptors. Curr. Biol. 7, 615–618.
Warren, H.S., Campbell, A.J., Waldron, J.C., Lanier, L.L., 2001. Biphasic
response of NK cells expressing both activating and inhibitory killer
Ig-like receptors. Int. Immunol. 13, 1043–1052.
Watzl, C., Stebbins, C.C., Long, E.O., 2000. NK cell inhibitory receptors
prevent tyrosine phosphorylation of the activation receptor 2B4
(CD244). J. Immunol. 165, 3545–3548.
Wende, H., Colonna, M., Ziegler, A., Volz, A., 1999. Organization of
the leukocyte receptor cluster (LRC) on human chromosome 19q13.4.
Mamm. Genome 10, 154–160.
Willcox, B.E., Gao, G.F., Wyer, J.R., Ladbury, J.E., Bell, J.I., Jakobsen,
B.K., van der Merwe, P.A., 1999. TCR binding to peptide-MHC
stabilizes a flexible recognition interface. Immunity 10, 357–365.
Wilson, M.J., Torkar, M., Trowsdale, J., 1997. Genomic organization of
a human killer cell inhibitory receptor gene. Tissue Antigens 49, 574–
579.
Wilson, M.J., Torkar, M., Milne, S., Jones, T., Sheer, D., Beck, S.,
Trowsdale, J., 2000. Plasticity in the organization and sequences of
human KIR/ILT gene families. Proc. Natl. Acad. Sci. U.S.A. 97, 4778–
4783.
Winter, C.C., Long, E.O., 1997. A single amino acid in the p58 killer
cell inhibitory receptor controls the ability of natural killer cells to
discriminate between the two groups of HLA-C allotypes. J. Immunol.
158, 4026–4028.
Winter, C.C., Gumperz, J.E., Parham, P., Long, E.O., Wagtmann, N., 1998.
Direct binding and functional transfer of NK cell inhibitory receptors
reveal novel patterns of HLA-C allotype recognition. J. Immunol. 161,
571–577.
Wu, J., Song, Y., Bakker, A.B., Bauer, S., Spies, T., Lanier, L.L., Phillips,
J.H., 1999. An activating immunoreceptor complex formed by NKG2D
and DAP10. Science 285, 730–732.
Yamanaka, S., Zhang, X.Y., Miura, K., Kim, S., Iwao, H., 1998. The
human gene encoding the lectin-type oxidized LDL receptor (OLR1)
is a novel member of the natural killer gene complex with a unique
expression profile. Genomics 54, 191–199.
Yen, J.H., Moore, B.E., Nakajima, T., Scholl, D., Schaid, D.J., Weyand,
C.M., Goronzy, J.J., 2001. Major histocompatibility complex class
I-recognizing receptors are disease risk genes in rheumatoid arthritis.
J. Exp. Med. 193, 1159–1167.
Yu, H., Fehniger, T.A., Fuchshuber, P., Thiel, K.S., Vivier, E., Carson,
W.E., Caligiuri, M.A., 1998. Flt3 ligand promotes the generation of a
distinct CD34(+) human natural killer cell progenitor that responds to
interleukin-15. Blood 92, 3647–3657.
Zappacosta, F., Borrego, F., Brooks, A.G., Parker, K.C., Coligan, J.E.,
1997. Peptides isolated from HLA-Cw∗ 0304 confer different degrees
of protection from natural killer cell-mediated lysis. Proc. Natl. Acad.
Sci. U.S.A. 94, 6313–6318.
Zenner, G., Vorherr, T., Mustelin, T., Burn, P., 1996. Differential and
multiple binding of signal transducing molecules to the ITAMs of the
TCR-zeta chain. J. Cell Biochem. 63, 94–103.
Zhang, W., Sommers, C.L., Burshtyn, D.N., Stebbins, C.C., DeJarnette,
J.B., Trible, R.P., Grinberg, A., Tsay, H.C., Jacobs, H.M., Kessler,
C.M., Long, E.O., Love, P.E., Samelson, L.E., 1999. Essential role of
LAT in T cell development. Immunity 10, 323–332.
Zhao, X.F., Nowak, N.J., Shows, T.B., Aplan, P.D., 2000. MAGOH
interacts with a novel RNA-binding protein. Genomics 63, 145–148.